



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Apolipoprotein E controls the development of monocyte-derived alveolar macrophages upon pulmonary inflammatory adaptation

Citation for published version:

Theobald, H, Bejarano, DA, Katzmarski, N, Haub, J, Schulte-Schrepping, J, Yu, J, Bassler, K, Ament, AL, Osei-Sarpong, C, Piattini, F, Vornholz, L, T'Jonck, W, Gyorfí, AH, Hayer, H, Yu, X, Sheoran, S, Al Jawazneh, A, Chakarov, S, Haendler, K, Brown, GD, Williams, DL, Bosurgi, L, Distler, J, Ginhoux, F, Ruland, J, Beyer, M, Greter, M, Bain, CC, Vazquez-Armendariz, AI, Kopf, M, Schultze, JL & Schlitzer, A 2024, 'Apolipoprotein E controls the development of monocyte-derived alveolar macrophages upon pulmonary inflammatory adaptation', *Nature Immunology*. <https://doi.org/10.1038/s41590-024-01830-z>

Digital Object Identifier (DOI):

[10.1038/s41590-024-01830-z](https://doi.org/10.1038/s41590-024-01830-z)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Nature Immunology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 **Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alveolar**
2 **macrophages upon pulmonary β -glucan-induced inflammatory adaptation**

3 Theobald H.^{1*}, Bejarano D.A.^{1*}, Katzmarski N.^{1*}, Haub J.^{1*}, Schulte-Schrepping J.^{2,3}, Yu J.¹, Bassler
4 K.², Ament A.L.⁴, Osei-Sarpong C.⁵, Piattini F.⁶, Vornholz L.^{7,8}, T'Jonck W.⁹, Györfi A.H.^{10,11}, Hayer
5 H.¹, Yu X.¹², Sheoran S.¹, Al Jawazneh A.^{13,14}, Chakarov S.¹⁵, Haendler K.¹⁶, Brown G.D.¹⁷, Williams
6 D.L.¹⁸, Bosurgi L.^{13,14}, Distler, J.^{10,11}, Ginhoux F.^{15,19,20}, Ruland J.^{7,8,21,22}, Beyer M.^{5,16}, Greter M.¹², Bain
7 C.C.⁹, Vazquez-Armendariz A.I.⁴, Kopf M.⁶, Schultze J.L.^{2,3,16}, Schlitzer A.¹

8 ¹Quantitative Systems Biology, Life & Medical Sciences Institute, University of Bonn, Bonn, Germany

9 ²Genomics & Immunoregulation, Life & Medical Sciences Institute, University of Bonn, Bonn, Germany

10 ³Systems Medicine, Deutsches Zentrum für Neurodegenerativen Erkrankungen (DZNE), Bonn, Germany

11 ⁴University of Bonn, Transdisciplinary Research Area Life and Health, Organoid Biology, Life & Medical
12 Sciences Institute, 53115 Bonn, Germany.

13 ⁵Immunogenomics & Neurodegeneration, German Center for Neurodegenerative Diseases, Bonn, Germany

14 ⁶Institute of Molecular Health Science, ETH Zürich, Zürich, Switzerland

15 ⁷Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich,
16 Munich, Germany

17 ⁸TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany

18 ⁹Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh
19 BioQuarter, UK

20 ¹⁰Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University,
21 Düsseldorf, Germany.

22 ¹¹Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University,
23 Düsseldorf, Germany

24 ¹²Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

25 ¹³I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

26 ¹⁴Protozoa Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

27 ¹⁵Shanghai Institute of Immunology, Shanghai JiaoTong School of Medicine, Shanghai, China

28 ¹⁶PRECISE Platform for Single Cell Genomics and Epigenomics at DZNE & University of Bonn, Bonn,
29 Germany

30 ¹⁷MRC Centre for Medical Mycology, University of Exeter, Exeter, UK

31 ¹⁸Department of Surgery and Center for Inflammation, Infectious Disease and Immunity, James H. Quillen
32 College of Medicine, East Tennessee State University, Johnson City, United States.

33 ¹⁹Singapore Immunology Network, Agency for Science, Technology and Research, Singapore

34 ²⁰INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France

35 ²¹German Center for Infection Research (DZIF), partner site Munich, Germany

36 ²²German Cancer Consortium (DKTK), partner site Munich, Germany

37

38 *Equally contributed

39 Correspondence to: andreas.schlitzer@uni-bonn.de

40 **Keywords:** Alveolar macrophages, monocytes, Dectin-1, Apolipoprotein E, Pulmonary Inflammation

41

42

43 **Summary**

44 The lung is constantly exposed to the outside world and optimal adaptation of immune responses is crucial for
45 efficient pathogen clearance. However, mechanisms that lead to lung-associated macrophages' functional and
46 developmental adaptation remain elusive. To reveal such mechanisms, we developed a reductionist model of
47 environmental intranasal β -glucan exposure, allowing for the detailed interrogation of molecular mechanisms of
48 pulmonary macrophage adaptation. Employing single-cell transcriptomics, high dimensional imaging, and flow
49 cytometric characterization paired with *in vivo* and *ex vivo* challenge models, we reveal that pulmonary low-grade
50 inflammation results in the development of Apolipoprotein E (ApoE) -dependent monocyte-derived alveolar
51 macrophages (ApoE⁺CD11b⁺ AM). ApoE⁺CD11b⁺ AMs expressed high levels of CD11b, ApoE, Gpnmb, and
52 Ccl6, were glycolytic, highly phagocytic, and produced large amounts of interleukin 6 upon restimulation.
53 Functional differences were cell intrinsic and myeloid cell-specific ApoE ablation inhibited Ly6c⁺ monocyte to
54 ApoE⁺CD11b⁺ AM differentiation dependent on M-CSF secretion, promoting ApoE⁺CD11b⁺ AM cell death and
55 thus impeding ApoE⁺CD11b⁺ AM maintenance. *In vivo*, β -glucan-elicited ApoE⁺CD11b⁺ AMs limited the
56 bacterial burden of *Legionella pneumophila* post-infection and improved the disease outcome *in vivo* and *ex vivo*
57 in a murine lung fibrosis model. Collectively these data identify ApoE⁺CD11b⁺ AMs generated upon
58 environmental cues, under the control of ApoE signaling, as an essential determinant for lung adaptation
59 enhancing tissue resilience.

60 **Introduction**

61 The lung is exposed to a variety of immunostimulatory agents shaping the its' immune responses ¹. How such
62 environmental non-pathological immune activation is controlled at the cellular and molecular level is poorly
63 understood. β -glucans are integral components of environmental pathogenic and non-pathogenic fungi and are
64 proposed as immune modulators ². Ambient concentrations of β -glucan oscillate over the course of the year and,
65 in combination with pathogen exposure, correlate with allergic rhinitis increases ³. Recognition of β -glucan by
66 Dectin-1 modulates systemic immune responses through a process termed innate immune memory ⁴, characterized
67 by increased cytokine responses of monocytes, upon a secondary heterologous stimulus, facilitated by a metabolic
68 and epigenetic rewiring, allowing a more efficient first line immune response ⁴⁻⁹. Lung-specific mechanism of β -
69 glucan, the organ where it is most often recognized, and how it acts as a non-genetic modifier of immune responses
70 to subsequent disease, remain unknown.

71 Alveolar space resident immune cells are the body's respiratory first line of defence, ensuring efficient immune
72 response induction against airborne pathogens, while regulating immune activation to ensure intact lung function
73 ¹⁰. Alveolar macrophages (AM) and monocytes constitute the major mononuclear phagocytes (MPs) found during
74 homeostasis in humans and mice within the alveolus. Alveolar AMs and monocytes express high amounts of
75 Dectin-1 and are highly plastic ¹¹. Dectin-1 signalling critically depends on spleen tyrosine kinase (Syk) which
76 upon activation triggers phospholipase C gamma 2 (PLC γ 2) dependent calcium release, downstream nuclear
77 factor of activated T-cells (NFAT) and extracellular signal-regulated kinase (ERK) activation. This cascade leads
78 to production of interleukin (IL) 2 and 10. Furthermore Syk activates CARD9 leading to nuclear factor kappa-
79 light-chain-enhancer of activated B cells (NF κ B) signalling and the release of tumor necrosis factor alpha
80 (TNF α) and IL-6. Additionally, Dectin-1 ligation directly induces reactive oxygen species (ROS) production via
81 activation of phosphoinositide 3 kinase (PI3K) ^{12,13}. Murine homeostatic AMs are embryonically derived with
82 only minor contribution of adult bone marrow (BM) homeostasis ^{14,15}. Pulmonary viral infection or radiation was
83 demonstrated induce differentiation of Ly6c⁺ monocytes into long-lived monocyte-derived alveolar macrophages
84 (MoAM) ¹⁶⁻¹⁸. During viral infection MoAM derived IL-6 is crucial for the defence against subsequent
85 *Streptococcus pneumoniae* infection ¹⁶. Finally, viral-induced environmental adaptation affects resident AMs-
86 dependent CD8⁺ T-cells rewiring, inducing efficient bacterial clearance ¹⁹.

87 Chronic lung diseases, like asthma or pulmonary fibrosis, hinge on environmental factors. Thus, understanding
88 environmental immune adaption in broncho-alveolar MPs is crucial for insights into cellular, functional, and
89 molecular consequences. ^{20,21-24}.

90 To investigate this we developed a reductionist model of a single low dose intranasal β -glucan exposure. Using
91 single-cell transcriptomic, functional *in vivo* and *ex vivo* analysis of cellular development function, this model
92 allowed us to dissect acute and chronic the molecular adaptations of macrophages upon environmental cues. We
93 show that a single intranasal β -glucan exposure induces developmentally and functionally modified
94 Apolipoprotein E (ApoE)⁺CD11b⁺ MoAMs, detected up to 21 days post β -glucan exposure. ApoE⁺CD11b⁺
95 MoAMs are glycolytic, highly phagocytic and release, upon activation, high amounts of IL-6. Functional changes
96 are cell-intrinsic and upon subsequent infection with *Legionella pneumophila* or a challenge by bleomycin-
97 induced fibrosis lead to improved *in vivo* outcomes. Molecularly, ApoE⁺CD11b⁺ MoAM are controlled by the
98 Dectin-1 - Card9 pathway, whereas maintenance of ApoE⁺CD11b⁺ MoAMs depends on paracrine ApoE and
99 macrophage colony-stimulating factor (M-CSF). Taken together, we identify ApoE as a crucial checkpoint for
100 low-grade inflammation-associated M-CSF controlled monocyte-to-macrophage differentiation triggered by the
101 Dectin-1 - Card9 pathway within the immune adapted microenvironment of lung.

102

103 **Results**

104 *Intranasal β -glucan induces ApoE⁺CD11b⁺ alveolar macrophages.*

105 The lung is constantly exposed to pollutants, sterile and non-sterile pathogens, and components thereof. Our
106 understanding of the cellular and molecular mechanisms of immune adaptation to these environmental cues is
107 limited. To investigate this, we developed a simplified model involving a single low-dose intranasal exposure to
108 β -glucan particles (200 μ g), mimicking environmental exposure²⁵. To assess the impact of this stimulation and
109 investigate its lasting effects, we examined bronchoalveolar lavage fluid (BALF) resident macrophages
110 (CD45⁺Lin⁻SSC^{int-hi}) of C57BL/6 mice seven days after intranasal PBS or β -glucan treatment using single-cell
111 transcriptomics (**Figure 1A, S1A-C**). Dimensionality reduction using uniform manifold approximation and
112 projection analysis (UMAP) and unsupervised clustering (Louvain) revealed five distinct transcriptional clusters
113 within the BALF (**Figure 1A, B**). Here, high expression of alveolar macrophage (AM) signature genes SiglecF
114 and Itgax identified all investigated cells as AMs (**Figure S1D, E**)²⁶. Further analysis identified Cluster 0, 1 as
115 subsets of resident AMs expressing Ear2, Wfdc21 and Hmox1, respectively^{26,27}. Cluster 2 (proliferating AM)
116 expressed genes linked to proliferation such as Top2a, Mki67, and Birc5²⁸. Cluster 3 (ApoE⁺ AMs), expressed
117 genes associated with a lipid-associated inflammatory monocyte-derived macrophage (MoMac) phenotype,
118 including Apoe, Cd63, Spp1, Gpnmb, and Trem2^{16,29,30}. Cluster 4 (ISG⁺ AMs), was characterized by expression
119 of interferon-stimulated genes (ISG), such as Ifit2, Ifit3, Ifi204, and Isg15 (**Figure 1B**). To determine which
120 cluster was associated with β -glucan-induced environmental adaptation, relative contribution of each stimulatory
121 condition to individual clusters was examined (**Figure 1C-E, S1F**). Here ApoE⁺ AMs were only present within
122 the BALF of β -glucan exposed mice seven days prior, concomitant with a reduction in proliferating AMs.
123 Previous studies suggested that CD11b expression on stimulated AMs serves marks enhanced inflammatory
124 potential^{31,32}. Therefore, we employed co-detection by indexing (CODEX)-enabled high-dimensional imaging to
125 characterize the phenotype of ApoE⁺ AMs at the protein level in the lung and in BALF seven days post- β -glucan
126 stimulation (**Figure 1F, S1G**)³³. ApoE⁺ AMs co-expressed the classical AM markers, CD11c and SiglecF, but
127 also expressed significant amounts of CD11b, ApoE, and GPNMB proteins (**Figure 1F, S1G**). Furthermore, to
128 confirm overlap of ApoE mRNA expression and CD11b protein expression, we measured ApoE mRNA levels
129 using PrimeFlow. ApoE mRNA signals were detectable only in BALF CD11b⁺ AMs isolated from mice
130 stimulated with β -glucan seven days prior (**Figure 1G**). Consequently, we refer to this AM subpopulation as
131 ApoE⁺CD11b⁺ AMs. To investigate the β -glucan-induced cellular dynamics of ApoE⁺CD11b⁺ AMs we monitored
132 the BALF from day 0 to day 21 post- β -glucan exposure using flow cytometry (**Figure 1H, I, S1H, I**). This analysis

133 revealed that, in line with the single-cell transcriptomic data, ApoE⁺CD11b⁺ AMs peaked at day seven post-β-
134 glucan inoculation and gradually declined until day 21 (**Figure 1H, I**). In agreement with this, we observed an
135 overall increase in total AMs peaking at day seven post-β-glucan exposure (**Figure S1J, K**). Generation of
136 ApoE⁺CD11b⁺ AMs was associated with a transient influx of neutrophils and eosinophils on days 1 and 3 (**Figure**
137 **S1L, M**). To confirm the macrophage identity of ApoE⁺CD11b⁺ AMs, SiglecF expression on CD11b⁻ AMs,
138 ApoE⁺CD11b⁺ AMs, and Ly6c⁺ monocytes was assessed. Both CD11b⁻ and ApoE⁺CD11b⁺ AMs expressed high
139 levels of SiglecF, whereas Ly6c⁺ monocytes did not, further establishing ApoE⁺CD11b⁺ AMs as part of the AM
140 compartment (**Figure S1N**). Finally, to understand abundance ApoE⁺CD11b⁺ AMs in total lung single-cell
141 suspensions, we quantified ApoE⁺CD11b⁺ AMs using flow cytometry (**Figure S1O**). ApoE⁺CD11b⁺ AMs were
142 also present in full lung suspensions, displaying similar quantity and marker profile as in BALF. In summary,
143 intranasal β-glucan induces ApoE⁺CD11b⁺ alveolar macrophages as a cellular response to environmental
144 stimulation.

145

146 *ApoE⁺CD11b⁺ AMs are derived from monocytes and depend on CCR2.*

147 Both acute and chronic inflammation induce the recruitment of MoMacs into the bronchoalveolar space^{16,31,34}.
148 To understand whether β-glucan-induced environmental adaptation induces a new resident alveolar macrophage
149 cell state or results in the recruitment and differentiation of Ly6c⁺ monocytes into ApoE⁺CD11b⁺ AMs, we tracked
150 the influx of Ly6c⁺ monocytes into the BALF using flow cytometry. Post-β-glucan stimulation, Ly6c⁺ monocytes
151 were recruited to the bronchoalveolar space, peaking three days after stimulation, remaining elevated on day 7,
152 and gradually declining from day 14 onwards (**Figure 2A, S2A**). To connect these findings with the emergence
153 of ApoE⁺CD11b⁺ AMs, we utilized the Ms4a3^{cre}Rosa26^{tdTomato} mice, enabling genetic tracing of the BM-derived
154 granulocyte-macrophage progenitors (GMP).

155 Genetic lineage tracing revealed that 86% ± 7.8% of ApoE⁺CD11b⁺ AMs were labelled with tdTomato, indicating
156 BM GMP lineage origin (**Figure 2B, C**). CODEX imaging showed co-expression of CD11b and tdTomato in
157 SiglecF⁺CD11c⁺ AMs within tissue sections from mice stimulated with β-glucan seven days prior, supporting
158 their GMP and monocyte origin (**Figure 2D**). To determine if Ly6c⁺ monocytes are systemically mobilized and
159 recruited to the lung from the BM following β-glucan stimulation, we assessed the abundance of Ly6c⁺ monocytes,
160 cMOP and GMP in the blood and BM, respectively (**Figure 2E, F, S2B-G**). This revealed a reduction in Ly6c⁺
161 monocytes in the blood, accompanied by a compensatory increase in BM Ly6c⁺ monocytes seven days after β-
162 glucan stimulation. To confirm the monocytic BM origin of ApoE⁺CD11b⁺ AMs, we utilized CCR2-deficient

163 mice, in which the recruitment of Ly6c⁺ monocytes into peripheral tissues is impaired³⁵. To investigate
164 dependence of ApoE⁺CD11b⁺ AMs on CCR2, we intranasally inoculated control and CCR2-deficient mice with
165 β -glucan and analysed the BALF seven days later using flow cytometry (**Figure 2G, S2H**). This analysis revealed
166 a significant reduction in ApoE⁺CD11b⁺ AMs in CCR2-deficient mice following β -glucan inoculation. In
167 summary, these results collectively demonstrate that ApoE⁺CD11b⁺ AMs induced by β -glucan exposure originate
168 from BM Ly6c⁺ monocytes in a CCR2-dependent manner.

169

170 *ApoE⁺CD11b⁺ AMs exhibit an elevated release of interleukin-6 (IL-6).*

171 MoMacs have been linked to heightened inflammatory responses following high-grade inflammatory and
172 infectious events, such as influenza A infection¹⁶. Specifically, the increased production of IL-6 is a hallmark
173 feature of functionally modified MoMacs during acute inflammation. However, it remains unclear whether BALF-
174 resident mononuclear cells functionally adapt to local low-grade inflammation. To address this, we investigated
175 the functional profile of AMs seven days after exposure to β -glucan. We isolated BALF AMs, and subsequently
176 re-stimulated them with PBS or lipopolysaccharide (LPS) for 24 hours *in vitro*. Analysis of IL-6 release in the
177 supernatants using ELISA revealed that *in vivo* β -glucan pre-exposed macrophages released significantly higher
178 amounts of IL-6 upon LPS re-stimulation, compared to PBS-pre-treated counterparts (**Figure 3A**). To identify the
179 cellular source responsible of increased IL-6 production, we purified BALF-resident CD11b⁻ and ApoE⁺CD11b⁺
180 AMs of intranasal β -glucan treated mice seven days earlier and restimulated them with LPS (**Figure 3B**). Only
181 ApoE⁺CD11b⁺ AMs released comparable amounts of IL-6 to those observed in complete BALF AM preparations
182 (**Figure 3A**). Subsequently, intracellular flow cytometric analysis demonstrated a significant increase in IL-
183 6⁺CD11b⁺ AMs following β -glucan exposure compared to PBS-exposed controls (**Figure 3C, S3A**). Our data
184 indicated that the generation of ApoE⁺CD11b⁺ AMs in response to β -glucan exposure depends on CCR2 (**Figure**
185 **2G**). To confirm that the increased IL-6 observed in *ex vivo* restimulated AMs can be directly attributed to CCR2-
186 dependent ApoE⁺CD11b⁺ AMs, we exposed CCR2-deficient and control mice to β -glucan. Seven days later, we
187 enriched BALF AMs were enriched, restimulated and restimulated with LPS for 24 hours *in vitro* (**Figure 3D**).
188 This analysis revealed that the elevated IL-6 levels observed in β -glucan-exposed BALF AMs are CCR2-
189 dependent, providing evidence that ApoE⁺CD11b⁺ AMs are the primary source of increased IL-6 during β -glucan-
190 induced environmental adaptation. Finally, to causally establish whether the enhanced IL-6 production is an
191 intrinsic cellular feature of ApoE⁺CD11b⁺ AMs, we transferred CD45.2⁺ BALF resident AMs into naïve CD45.1⁺
192 mice five days after β -glucan-induced environmental adaptation. Two days later, we restimulated BALF AMs

193 with LPS *in vitro* (**Figure 3E, S3B, C**). Transfer of β -glucan-experienced BALF AMs led to an increased IL-6
194 production upon *in vitro* restimulation of AMs within the recipient mouse. These findings causally establish the
195 intrinsic β -glucan-induced functional change in ApoE⁺CD11b⁺ AMs.

196

197 *β -glucan aids lung bacterial defense and experimental fibrosis recovery.*

198 Previous studies associated altered cytokine responses following systemic β -glucan stimulation with increased
199 glycolysis in MPs^{7,8}. To investigate this in our system, we measured glycolysis. This revealed a significant
200 increase in glycolysis, glycolytic capacity, and reserve seven days after β -glucan exposure in BALF AMs (**Figure**
201 **4A, B, S4A, B**). In addition, induction of glycolysis in MPs is associated with enhanced phagocytosis^{36,37}. Thus,
202 we assessed BALF AM phagocytosis of *Staphylococcus aureus-coated* particles *in vitro* isolated from mice
203 adapted to PBS or β -glucan seven days prior. This demonstrated a significant increase in phagocytic activity in
204 BALF AMs isolated from β -glucan-adapted mice but not PBS-adapted (**Figure 4C, D, S4C, D**). This prompted
205 us to investigate the *in vivo* functional impact of intranasal β -glucan adaptation in response to acute bacterial
206 challenge. We infected C57BL/6 mice, β -glucan-adapted or PBS-adapted seven days earlier, with *Legionella*
207 *pneumophila* and analysed the BALF's bacterial burden and cellular composition two days post-infection³⁸. β -
208 glucan-adapted mice exhibited a significant reduction in bacteria detected in BALFs, along with an increased
209 count of proinflammatory macrophages associated with bacterial clearance (**Figure 4E, F, S4E**).

210 Furthermore, we examined whether β -glucan adaptation had effects beyond the modulation of acute bacterial
211 infection using bleomycin-induced experimental lung fibrosis. β -glucan-adapted mice showed significantly higher
212 survival rates, lower disease burden, and reduced weight loss over a 14-day observation period post-bleomycin
213 inoculation (**Figure S4F-I**). Moreover, the pro-resolution associated effectors, IL-4 and IL-33, were enhanced on
214 day 3 post-bleomycin inoculation, while on day 14 post-bleomycin TSLP decreased in β -glucan adapted mice
215 (**Figure S4J-L**). No difference in lung fibrotic area was observed (**Figure S4M, N**). These findings highlight the
216 substantial regulatory role of ApoE⁺CD11b⁺ AMs elicited by environmentally adaptation in the control and
217 severity of acute and chronic inflammation. To elucidate the direct effect of ApoE⁺CD11b⁺ AMs on the
218 development of lung fibrosis, we generated bronchoalveolar lung organoids (BALOs) containing myofibroblasts
219 ³⁹. We treated them with transforming growth factor-beta (TGF- β) to induce a fibrotic response. BALF AMs
220 isolated from β -glucan or PBS-adapted mice were added to day 21 BALOs 24 h before TGF- β pro-fibrotic
221 stimulation and co-cultured for 48 hours. Adding TGF- β to BALOs led to the increased production of fibroblast
222 smooth muscle actin (SMA), a hallmark of lung fibrosis. We quantified SMA production in β -glucan or PBS-

223 adapted AMs-supplemented fibrotic BALOs. We observed a significant reduction in SMA production when β -
224 glucan-adapted AMs were added, while the addition of PBS-adapted AMs showed no effect (**Figure 4G, H, S4O**).
225 In conclusion, functional *in vivo* and *in vitro* data establish ApoE⁺CD11b⁺ AMs as crucial environmentally
226 induced modulators of lung inflammation, providing valuable insights into the molecular mechanisms underlying
227 their role in mitigating fibrosis.

228

229 *β -glucan induces ApoE⁺CD11b⁺ AMs via Dectin-1/Card9.*

230 β -glucan is recognized by various receptors, including CR3, Dectin-1 and CD5⁴⁰⁻⁴². Dectin 1 is most prominently
231 on MPs. To understand how Dectin 1 regulates ApoE⁺CD11b⁺ AMs, we flow cytometrically profiled its'
232 expression on BALF macrophages (**Figure 5A**). This revealed that homeostatic Dectin-1 expression is largely
233 confined to resident AMs with only a small fraction of monocytes expressing Dectin-1. To assess the role of
234 Dectin-1 for development of ApoE⁺CD11b⁺ AMs, we intranasally inoculated control or Dectin1^{-/-} mice with β -
235 glucan and flow cytometrically analysed BALF resident immune cells seven days later. This revealed that
236 generation of ApoE⁺CD11b⁺ AMs is dependent on Dectin-1 expression, whereas initial inflammatory recruitment
237 of Ly6c⁺ monocytes to the BALF is not (**Figure 5B, C**). Next, to understand whether immune cell-intrinsic or
238 stromal cell recognition via Dectin-1 is critical for the development of ApoE⁺CD11b⁺ AMs and thus
239 environmental adaptation, we transferred Dectin1^{-/-} or control (CD45.2⁺) BM into lethally irradiated CD45.1⁺
240 control mice and analysed their BALF seven days post environmental adaption by β -glucan. Here, generation of
241 ApoE⁺CD11b⁺ AMs was entirely dependent on hematopoietic expression of Dectin-1 (**Figure 5D, S5A, B**).
242 CARD9 mediates activation of Nfkb by Dectin-1^{12,13,43}. To investigate if ApoE⁺CD11b⁺ AMs require CARD9
243 for their development we treated lethally irradiated mice reconstituted with Card9^{-/-} or control BM with β -glucan
244 or PBS and flow cytometrically analysed the BALF seven days later. This revealed that development of
245 ApoE⁺CD11b⁺ AMs depends on Dectin-1-elicited Card9-dependent signalling (**Figure 5E, S5C, D**). Next, we
246 investigated whether the loss of ApoE⁺CD11b⁺ AMs by abrogating Dectin-1 or Card9 signalling leads to a loss of
247 increased IL-6 secretion upon *in vitro* LPS restimulation in BALF macrophages. In line with the data obtained in
248 the CCR2^{-/-} mouse model, enhanced IL-6 secretion was abolished in the absence of Dectin-1 or Card9 signalling
249 and thus can be attributed to ApoE⁺CD11b⁺ AMs (**Figure 5F, G**).

250

251 *β -glucan triggers ApoE⁺CD11b⁺ AM differentiation via myeloid ApoE.*

252 ApoE is expressed in various MoMac populations associated with different low-grade or chronic inflammatory
253 diseases but its role in monocyte-to-macrophage differentiation and maintenance remains unexplored^{16,29}. During
254 β -glucan-induced environmental adaptation, ApoE was highly expressed in ApoE⁺CD11b⁺ AMs and detectable
255 at the protein level as early as one day after intranasal β -glucan stimulation, coinciding with BALF Ly6c⁺
256 monocyte recruitment (**Figure 6A, B, 2A**). To elucidate the role of ApoE in the environmental adaptation of the
257 lung MP repertoire, we intranasally inoculated ApoE^{fllox}LysM^{Cre} mice, which lack ApoE expression within the
258 myeloid lineage, with β -glucan. Next, we flow cytometrically analysed the composition of the BALF MP
259 compartment seven days later. β -glucan-stimulated ApoE^{fllox}LysM^{Cre} mice did not exhibit increased numbers of
260 BALF Ly6c⁺ monocytes and, as a consequence, failed to generate ApoE⁺CD11b⁺ AMs (**Figure 6C, D, S6A, B**).
261 Next we examined whether loss of myeloid ApoE influences the observed feedback on blood and BM Ly6c⁺
262 monocytes. Myeloid ApoE deficiency abrogated the decrease in blood monocytes and the compensatory increase
263 in BM Ly6c⁺ monocytes observed in control mice. Myeloid ApoE deficiency showed no effect on cMOPs or
264 GMPs seven days after β -glucan stimulation (**Figure S6C-F**). Subsequently, we investigated whether ApoE
265 controls the generation of ApoE⁺CD11b⁺ AMs through paracrine or autocrine signalling, as both modes have been
266 described previously^{44,45}. Here, we generated mixed BM chimeras with a 50:50 ratio of wildtype (CD45.1⁺) and
267 ApoE^{fllox}LysM^{Cre} (CD45.2⁺) cells or congenic mixed wildtype (CD45.1⁺) : wildtype (CD45.2⁺) control chimeras.
268 After reconstitution, we intranasally stimulated them with β -glucan and flow cytometrically analysed their BALF
269 MP repertoire seven days later. This revealed that both WT/WT and WT/ApoE^{fllox}LysM^{Cre} chimeras efficiently
270 generated ApoE⁺CD11b⁺ AMs seven days after β -glucan exposure, supporting a paracrine signalling mode
271 (**Figure 6E, S6G, H**). Next, we examined the contribution of ApoE-deficient CD45.2⁺ cells to the pool of total
272 ApoE⁺CD11b⁺ AMs. We found that both ApoE-proficient (CD45.1) and deficient (CD45.2) cells equally
273 contributed to the pool of β -glucan stimulated ApoE⁺CD11b⁺ AMs (**Figure 6F**). This demonstrate that a paracrine
274 myeloid cell-derived source of ApoE is sufficient to rescue the generation of ApoE⁺CD11b⁺ AMs during
275 environmental adaptation in the lung.

276

277 *Myeloid-derived Apolipoprotein E controls survival of ApoE⁺CD11b⁺ AMs by regulation of cholesterol storage*
278 *and M-CSF secretion*

279 To elucidate ApoE's role in the differentiation and survival of ApoE⁺CD11b⁺ AM, we conducted experiments to
280 determine whether myeloid-derived ApoE influences the initial commitment of Ly6c⁺ monocytes to or the
281 maintenance and survival of MoMacs. We used control and ApoE^{fllox}LysM^{Cre} mice three days after intranasal β -

282 glucan exposure. On day three post β -glucan exposure similar numbers of BALF Ly6c⁺ monocytes were present
283 in control and ApoE^{flox}LysM^{Cre} mice. This suggests that ApoE does not regulate the initial commitment to the
284 macrophage lineage or the recruitment of monocytic precursors to the BALF. However, our results established a
285 critical time window during which ApoE is essential for monocyte-to-macrophage differentiation following β -
286 glucan inoculation (**Figure 7A, B, S7A, B**). To investigate potential molecular dysregulation caused by the
287 absence of ApoE in differentiating macrophages, we assessed intracellular cholesterol content and distribution of
288 BALF ApoE⁺CD11b⁺ AMs three days after β -glucan stimulation. This revealed that ApoE-deficient CD11b⁺ AMs
289 have increased intracellular cholesterol, as indicated by filipin staining (**Figure 7C, D**). Previous data linked
290 dysregulated ApoE signalling to cholesterol accumulation in the endoplasmic reticulum and a reduction in protein
291 synthesis⁴⁶. To test these mechanisms in our experimental system of monocyte-to-macrophage differentiation, we
292 analysed the co-localization of BODIPY-cholesterol with the endoplasmic reticulum-associated protein
293 Calreticulin and early or late endosome markers (EEA1 and LAMP1) using confocal microscopy. This revealed
294 that, in ApoE-deficient differentiating macrophages three days after β -glucan exposure, BODIPY-cholesterol co-
295 localizes with calreticulin, accumulating at the endoplasmic reticulum (**Figure 7E, F**). M-CSF-releasing
296 monocytes differentiating into macrophages has been described to be crucial for lung monocyte-to macrophage
297 differentiation⁴⁷. To assess whether aberrant cholesterol accumulation affects the M-CSF-M-CSFR macrophage
298 survival circuit, we monitored BALF and lung tissue intra- and extracellular M-CSF secretion. Here, ApoE-
299 deficiency resulted in a reduction of both BALF and lung tissue extracellular and intracellular production of M-
300 CSF on day one and three after β -glucan exposure (**Figure 7G, H, S7C-E**), leading to an increase in TUNEL⁺
301 ApoE-deficient CD11b⁺ AMs in ApoE^{flox}LysM^{Cre} mice (**Figure 7I**). To determine if the loss of M-CSF plays a
302 crucial molecular role in the loss of differentiating monocytes to macrophages following β -glucan-induced
303 environmental adaptation, we employed antibody-mediated M-CSF receptor (CSF-1R) blockade on days 0 and 3
304 after β -glucan stimulation and analysed treated and control animals seven days later. Mice treated with anti-CSF-
305 1R-blocking antibody exhibited significantly lower numbers of ApoE⁺CD11b⁺ AMs seven days after β -glucan
306 inoculation, underscoring the importance of M-CSF in the monocyte-to-macrophage differentiation process
307 following β -glucan stimulation (**Figure 7J, S7F-I**). Taken together this suggests ApoE as a central regulator of
308 pulmonary monocyte-to-macrophage differentiation and survival via the M-CSF signalling axis upon β -glucan-
309 induced environmental adaptation.

310

311 **Discussion**

312 Within our modern-day environment, the lung is constantly exposed to a plethora of sterile immunostimulatory
313 components. However, the developmental, functional and molecular consequences for lung-resident macrophages
314 are incompletely understood. Here, we show that a single non-pathologic intranasal β -glucan stimulus induces the
315 development of MoAM, which highly express CD11b and ApoE and are characterised by their superior IL-6
316 production capacity in response to secondary LPS stimulation. Additionally, ApoE⁺CD11b⁺ AMs are glycolytic,
317 highly phagocytic, and modify the outcome of a secondary bacterial infection and of a chronic fibrotic response
318 *in vivo*. Molecularly this is instructed by Dectin-1 mediated recognition of β -glucan and its signalling adapter
319 adaptor protein CARD9. Further analysis revealed a crucial role of ApoE for the maintenance of BALF-resident
320 ApoE⁺CD11b⁺ AMs via the control of macrophage-derived M-CSF. This reveals that ApoE is a crucial checkpoint
321 for monocyte to macrophage differentiation in the face of environmental adaptation and couples cellular
322 cholesterol metabolism to differentiation and function.

323 Prior studies examined the development of MoAMs during viral, bacterial and fungal infections, radiation or
324 bleomycin-induced fibrosis^{16,18,38,48-51}. However, how broncho-alveolar macrophages adapt their transcriptome,
325 metabolism and function to ambient immune-stimulatory components beyond the effects of the acute recognition
326 of such stimuli remains poorly understood⁵². Here, we show that although the initial pulmonary inflammation
327 evoked by β -glucan is minimal, functionally modified MoAMs arise from Ly6c⁺ monocytes within the BALF, a
328 process prior affiliated to e.g. viral or bacterial infection. This validates the model as suitable for low-grade
329 environmentally induced inflammation. ApoE⁺CD11b⁺ AMs are induced for up to 21 days post β -glucan
330 stimulation leading to functional modification of the macrophage repertoire in the lung, demonstrating the
331 importance of low-grade inflammatory sterile insults in shaping the overall immune competence of the lung-
332 resident macrophage repertoire.

333 β -glucan, a cell wall component of many pathological and non-pathological fungi, can be found within ambient
334 air²⁵. During fungal infection, monocytes and MoMacs are major antifungal effectors, via reactive oxygen species
335 and the activation of antifungal neutrophils, in mice and man^{50,53,54}. Furthermore, during the later stage of fungal
336 pathogenesis, monocyte descendants are important for induction of CD4⁺ T-cell responses⁵¹.

337 Recently studies evaluated the role of β -glucan for the induction of innate immune training systemically but did
338 not examine its effects at the level of the tissue^{4,55}. Systemically β -glucan-induced functional modulations were
339 accompanied by the induction of glycolysis and the enhanced release of the pro-inflammatory cytokines IL-6 and
340 TNF α in circulating Ly6c⁺ monocytes similar to β -glucan-induced functional adaptation in the lung. Systemic β -

341 glucan administration expands BM GMP / MPP like progenitors, resulting in enhanced pathogen clearance or
342 tissue maladaptation ⁵⁶⁻⁵⁸. We show that pulmonary β -glucan administration only minimally affects BM
343 progenitors and that generation of ApoE⁺CD11b⁺ AMs induces cMOP expansion and recruitment of CCR2-
344 dependent Ly6c⁺ monocytes to the lung. Dectin-1 recognizes β -glucan upon challenge; Dectin-1 downstream
345 signaling is heterogenous and determines the functional output. We show that tissue adaptation induces Dectin-1
346 CARD9-dependent signalling circuits, in concordance with increased IL-6 levels, most probably via activation of
347 Nfkb signalling. Finally, β -glucan-induced macrophages upregulate ApoE, a protein demonstrated to be part of
348 various disease-specific MoMac gene signatures, e.g. during influenza infection, lung fibrosis, or obesity ^{16,29,48}.
349 Its functional role in MoMac development was not investigated. In hematopoietic stem cells ApoE was shown to
350 inhibit proliferation and subsequent progenitor maturation by controlling sensitivity towards granulocyte
351 macrophage stimulating factor and IL-3 ⁵⁹. We show that myeloid-specific deletion of ApoE leads to the
352 accumulation of cholesterol at the endoplasmatic reticulum, loss of M-CSF production and increased cell death
353 ultimately inhibiting development of long-lived ApoE⁺CD11b⁺ AMs upon intranasal β -glucan challenge. ApoE⁺
354 MoMac are also found in white adipose tissues during obesity, a condition conferring training-like feature to MPs
355 or during influenza-induced lung inflammation supporting the crucial role of ApoE for the development of
356 functionally adapted macrophages during inflammation ^{29,60}. Other work has established functional Nfkb-
357 responsive elements within the ApoE gene and CARD9 directly activates Nfkb thus linking activation of
358 inflammatory Nfkb responses to the induction of inflammatory adaptation in MoMacs.
359 Collectively we provide evidence that a single non-pathological environmental stimulation via the Dectin-1 –
360 CARD9 axis generates inflammation-experienced MoMacs, which modify subsequent pulmonary acute and
361 chronic inflammation under the control of ApoE, thus molecularly linking macrophage inflammatory amplitude
362 to lung resilience and disease susceptibility.

363 **Acknowledgments**

364 We thank Dina Hüsson, Stephanie Weber (Beyer lab) for technical assistance. This study was funded by the
365 Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy
366 – EXC2151 – 390873048 (A.S., J.L.S), SFB 1454-P05-432325352 (A.S.), SFB 1454-P16-432325352 (M.B.),
367 IRTG 2168 272482170 (M.B., J.L.S.), SCHU 950/8-1 (J.L.S), RU 695/12 -1 (J.R.), Emmy Noether research grant
368 (SCHL2116/1 to AS), the BMBF-funded excellence project Diet–Body–Brain (DietBB) (J.L.S.), and the
369 European Research Council (ERC) under the European Union's Horizon 2020 research and innovation
370 programme (grant agreement No 834154 (J.R.); SYSCID 733100 (J.L.S.)). This research was partly funded by
371 Wellcome Trust [Grant number 217163, 102705] the Medical Research Council Centre for Medical Mycology at
372 the University of Exeter for funding (MR/N006364/2) (G.B) and Sir Henry Dale Fellowship jointly awarded by
373 the Wellcome Trust and by the Royal Society (Grant number 206234/Z/17/Z) (C.C.B). For the purpose of open
374 access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version
375 arising from this submission. W.T. is funded by a UKRI Postdoctoral Guarantee Fellowship (EP/X025071/1).
376 M.G. and X.Y. were funded by the Swiss National Science Foundation (310030_184915).

377

378 **Author contributions statement**

379 Conceptualization: H.T., D.A.B., J.H., N.K., A.S.; Formal Analysis and Investigation: H.T., D.A.B., J.H., N.K.,
380 J.S-S., J.Y., K.B., A.L.A., C.O.S., F.P., M.K., L.V., Y.X., M.G., L.B., W.T., C.C.B., S.S., A.I.V.A., A.H.G., J.D.,
381 A.A., S.C., K.H., G.B., D.L.W., F.G., J.R., M.B., J.L.S.; Writing: H.T., D.A.B., J.H., A.S.; Supervision: A.S..

382

383 **Competing interests Statement**

384 **The authors declare no competing interests.**

385

386 **Figure Legends**

387 **Figure 1 Intranasal β -glucan exposure generates environmentally adapted ApoE⁺CD11b⁺ alveolar**
388 **macrophages within the broncho-alveolar space.**

389 (A-E) Single-cell RNA sequencing of the broncho-alveolar lavage fluid (BALF) of male 8-12 weeks old
390 C57BL/6J (WT) mice after intranasal stimulation with 200 μ g β -glucan or PBS (n=10202 cells). Seven days after
391 exposure, cells of three mice per condition were harvested and sorted for SSC^{hi}, Lin⁻ (B220, CD19, CD3 ϵ , Nk1.1,

392 Ter-119), DRAQ7⁻ singlets (n=3 mice, one independent experiment). (A) Uniform-manifold approximation and
393 projection (UMAP) analysis of both conditions combined shows five different clusters. (B) Heatmap of top ten
394 highly expressed genes for each of the five clusters. (C, D) UMAP from (A) separated by PBS (C, n= 4845 cells)
395 or β -glucan (D, n= 5357 cells) condition. (E) Percentage of contribution of the five annotated clusters to overall
396 cells split by conditions. (F) 5 μ m frozen section of the left lobe of the lung of a *Ms4a3-cre*^{Rosa26TOMATO} mouse 7
397 days after β -glucan exposure stained with a 17-plex CODEX antibody panel. Overlay image shows the markers
398 used to identify AM populations. Single stainings of these markers are shown in grayscale. Filled arrows indicate
399 ApoE⁺CD11b⁺ AMs, whereas open arrows CD11b⁻ AMs. Scale bar represents 100 μ m in the large image and 10
400 μ m for the enlargements (n= one representative mouse of two independent experiments). (G) Detection of *ApoE*
401 mRNA expression in the AM subsets of the BALF 7 days after intranasal PBS or β -glucan exposure in WT mice
402 by Prime Flow (n= 3 mice pooled per group, one out of two independent experiments shown). (H, I) Flow
403 cytometric quantification of absolute numbers (H) or frequency (I) of ApoE⁺CD11b⁺ AM
404 (CD45⁺SiglecF⁺CD64⁺CD11c⁺CD11b⁺) in the BALF in a time course from 1 to 21 days post β -glucan stimulation
405 of WT mice (n= 9-10 mice, two independent experiments). Data in (H, I) are depicted as mean \pm SD, ordinary
406 one-way ANOVA with Tukey's multiple comparisons.

407

408 **Figure 2 ApoE⁺CD11b⁺ AMs are monocyte-derived and CCR2-dependent.**

409 (A) Flow cytometric quantification of absolute Ly6c⁺ monocyte (CD45⁺Ly6g⁺SiglecF⁻CD64^{int}CD11b⁺Ly6c⁺)
410 numbers in the BALF 1 to 21 days post β -glucan stimulation of WT mice (n=9-10 mice, two independent
411 experiments). (B, C) Flow cytometric analysis of BALF from *Ms4a3-cre*^{Rosa26TOMATO} mice seven days after
412 intranasal PBS or β -glucan stimulation (n=8, two independent experiments). (B) Percentage of tdTomato⁺
413 labelling in CD11b⁻ and ApoE⁺CD11b⁺ AM and (C) proportion of tdTomato⁺ labelling in CD11b⁻ and
414 ApoE⁺CD11b⁺ AM compared to monocytes (CD45⁺SiglecF⁻Ly6g⁻CD11b⁺F4/80⁺). (D) CODEX multiplexed
415 immunostaining of the left lobe of a *Ms4a3-cre*^{Rosa26TOMATO} mouse 7 days after β -glucan exposure (enlargement
416 from Fig. 1F). Filled arrowheads indicate ApoE⁺CD11b⁺ AMs, whereas empty arrowheads indicate CD11b⁻ AMs.
417 tdTomato reporter signals are represented in red. Scale bar represents 50 μ m. (E, F) Absolute counts of Ly6c⁺
418 monocytes in the blood (E) or in the BM (F) of WT mice seven days after PBS or β -glucan by flow cytometry (n
419 = 6 mice, two individual experiments). (G) Flow cytometric quantification of absolute ApoE⁺CD11b⁺ AM
420 numbers in the BALF seven days after β -glucan exposure in WT or CCR2^{-/-} mice (n=7-8 mice, two individual

421 experiments). Data are depicted as mean \pm SD, (A, G) ordinary one-way ANOVA with Tukey's multiple
422 comparisons, (B, E, F) unpaired two-tailed student's *t*-test).

423

424 **Figure 3 ApoE⁺CD11b⁺ AMs show increased release of interleukin 6 and induction of glycolysis.**

425 (A-C) BALF cells were harvested from WT or *Ms4a3-cre*^{ROSA26TOMATO} mice seven days after intranasal exposure
426 with PBS or β -glucan and subsequently restimulated *in vitro* with LPS for 18h. (A) Quantification of IL-6 protein
427 levels by ELISA in the cell culture supernatant 24 h after LPS restimulation of WT mice (n=13-15 mice, three
428 individual experiments). (B) CD11b⁺ Ms4a3⁺ AM and CD11b⁻ Ms4a3⁻ AM were sorted from the pooled BALF
429 of PBS or β -glucan stimulated *Ms4a3-cre*^{ROSA26TOMATO} mice and seeded with 0.2x10⁵ cells per well prior to LPS
430 restimulation (n= 9 mice for PBS, n= 31 mice for β -glucan, one dot represents the pooled supernatant of two
431 technical replicate wells, here minimum 9 data points per group, two individual experiments). (C) Percentage of
432 IL-6⁺ cells among ApoE⁺CD11b⁺ AM after restimulation with LPS for 6-8 h followed by intracellular staining
433 and flow cytometric analysis (n=6-7 mice, two individual experiments). (D) Quantification of IL-6 protein levels
434 by ELISA in the cell culture supernatant 24 h after restimulation with LPS of WT and CCR2^{-/-} mice (n=9-10 mice,
435 two individual experiments). (E) BALFs of PBS or β -glucan experienced CD45.2 WT mice were harvested and
436 pooled five days after stimulation. 2x10⁵ cells in 35 μ l were intratracheally transferred into CD45.1 mice.
437 Quantification of IL-6 protein levels by ELISA in the cell culture supernatant after restimulation with LPS 48 h
438 post transfer (n=7-8 mice, two individual experiments). Data are depicted as mean \pm SD, (A-E) ordinary one-way
439 ANOVA with Tukey's multiple comparisons.

440

441 **Figure 4 Environmental adaptation induced by β -glucan significantly improve pulmonary bacterial
442 clearance and outcome of bleomycin-induced fibrosis**

443 (A, B) Extracellular acidification rate (A) and glycolysis (B) in BALF cells seven days after PBS or β -glucan
444 stimulation of WT mice measured by Seahorse (n=6 mice, one independent experiment). (C, D) AM cells from
445 day seven PBS or β -glucan experienced WT mice were selected by adherence and subsequently treated with 2.5
446 μ m pHrodo *S.aureus* bioparticles (n=3 mice pooled per condition, technical replicates: 6 control wells, 12-19
447 treated wells per group, one out of two independent experiments shown). (C) Representative curve of absolute
448 phagocytosis⁺ AM numbers over the time course of 7 h (here shown as mean \pm SD of all technical replicates). (D)
449 Absolute numbers of phagocytosis⁺ AM 2 h after adding the pHrodo *S.aureus* bioparticles. (E, F) C57BL/6J WT
450 mice were intranasally stimulated with PBS or β -glucan followed by intratracheal infection with 5x10⁶ CFU

451 *Legionella pneumophila* at day seven post primary stimulation and analysis at day nine (n=9-10 mice, two
452 independent experiments). Quantification of bacterial load in BALF (E) and absolute numbers of ApoE⁺CD11b⁺
453 AM by flow cytometry nine days post primary stimulation (F). (G, H) Representative confocal images (G) and
454 SMA area quantification (H) of BALOs co-cultured with PBS- or β -glucan-experienced AM 48 h after induction
455 of fibrosis via TGF- β . Seven days after stimulation, 2.5×10^4 AM of PBS or β -glucan experienced WT mice were
456 co-cultured with day 21 lung BALOs for 24 h. AM-organoid co-cultures were subsequently treated with 1.05
457 ng/ml TGF- β for 48 h prior to fixation and antibody staining. Myofibroblasts were stained for α -SMA (n=6-8
458 organoids per condition from two replicate wells, one out of two independent experiments shown). Scale bars in
459 (G) represent 50 μ m. Data are depicted as mean \pm SD, (B, E, F) unpaired two-tailed student's *t*-test, (D) ordinary
460 one-way ANOVA with Tukey's multiple comparisons, (H) Two-tailed Mann-Whitney test.

461

462 **Figure 5 Generation of ApoE⁺CD11b⁺ AMs by β -glucan is dependent on the Dectin-1 – Card9 signalling**
463 **axis.**

464 (A) Percentage of monocyte and macrophage populations contributing to Dectin-1⁺ cells in the WT mouse lung
465 pre-gated on CD45⁺Lin⁻Ly6g⁻CD64⁺ cells (n=11 mice, two independent experiments) by flow cytometry. (B, C)
466 Absolute ApoE⁺CD11b⁺ AM (B) and Ly6c⁺ monocyte (C) numbers in the BALF seven days after PBS or β -glucan
467 exposure in WT or Dectin1^{-/-} mice (n=5-9, two independent experiments) by flow cytometry. (D, E) Absolute
468 ApoE⁺CD11b⁺ AM numbers in the BALF seven days after PBS or β -glucan exposure in Dectin1^{-/-} (D, n=4-10
469 mice, two independent experiments) or CARD9^{-/-} (E, n=8-9 mice, two independent experiments) BM chimeras
470 by flow cytometry. (F) Quantification of IL-6 protein levels by ELISA in the cell culture supernatant 24 h after
471 LPS restimulation of WT and Dectin1^{-/-} mice (n=7-10 mice, two independent experiments). (G) Quantification of
472 IL-6 protein levels by ELISA in the cell culture supernatant 24 h after LPS restimulation of WT and CARD9^{-/-}
473 mice (n=9-10 mice, independent experiments). Data are depicted as mean \pm SD, (B-G) ordinary one-way ANOVA
474 with Tukey's multiple comparisons.

475

476 **Figure 6 Paracrine myeloid-derived Apolipoprotein E controls ApoE⁺CD11b⁺ AM differentiation upon β -**
477 **glucan-induced environmental adaptation.**

478 (A) Violin plot of *ApoE* RNA expression levels in the BALF seven days after β -glucan exposure by scRNA seq.
479 (B) WT mice were stimulated with β -glucan and BALF was harvested at different time points. Plot shows ApoE
480 protein levels in the BALF measured by ELISA (n=4-5 mice, one independent experiment). (C, D) Absolute

481 numbers of ApoE⁺CD11b⁺ AM (C) and Ly6c⁺ monocytes (D) seven days after intranasal β -glucan exposure of
482 control or ApoE^{fllox}LysM^{Cre} mice by flow cytometry (n=8-10 mice, three independent experiments). (E, F) Lethally
483 irradiated CD45.1⁺/CD45.2⁺ male mice were reconstituted with 1.5x10⁶ CD45.1⁺ mixed with CD45.2⁺ BM cells
484 (WT/WT) or with CD45.1⁺ mixed with ApoE^{fllox}LysM^{Cre} CD45.2⁺ BM cells (WT/ ApoE^{fllox}LysM^{Cre}) for 12 weeks
485 and subsequently intranasally stimulated with PBS or β -glucan (n=8-9 mice, two independent experiments). Flow
486 cytometric quantification of ApoE⁺CD11b⁺ AM numbers (E) and contribution of donor cells (CD45.1⁺ or
487 CD45.2⁺) to the ApoE⁺CD11b⁺ AM pool (F) seven days after exposure. Data are depicted as mean \pm SD, (B-F)
488 ordinary one-way ANOVA with Tukey's multiple comparisons.

489

490 **Figure 7 Myeloid-derived Apolipoprotein E controls survival of ApoE⁺CD11b⁺ AMs by regulation of**
491 **cholesterol storage and M-CSF secretion.**

492 (A-B) Absolute numbers of ApoE⁺CD11b⁺ AM (A) and Ly6c⁺ monocytes (B) three days after intranasal β -glucan
493 exposure in control or ApoE^{fllox}LysM^{Cre} mice (n=7-8, two independent experiments) by flow cytometry. (C, D)
494 BALF of PBS or β -glucan stimulated control or ApoE^{fllox}LysM^{Cre} mice was harvested three days after exposure,
495 seeded and fixed after 2 h. Filipin staining was performed followed by immunofluorescence analysis.
496 Representative images are shown in (C). Scale bars represent 5 μ m. Plot in (D) shows mean filipin signal
497 intensities of individual ApoE⁺CD11b⁺ AM in the different conditions (n=3 mice per condition, two independent
498 experiments). (E, F) Three days post stimulation of PBS or β -glucan stimulated control or ApoE^{fllox}LysM^{Cre} mice,
499 AM from the BALF were selected by adherence and afterwards incubated with 0.5 μ M BODIPY-Cholesterol
500 overnight. Cells were fixed for 15 min the next day and immunofluorescence was performed. (E) Representative
501 confocal images, the scale bar represents 5 μ m. (F) Quantification of overlapping signals of BODIPY-Cholesterol
502 and the organelle markers Calreticulin (ER), EEA1 (endosomes) and LAMP1 (lysosomes) (n=2 mice per
503 condition, two independent experiments). (G) BALF of PBS or β -glucan stimulated control or ApoE^{fllox}LysM^{Cre}
504 mice was harvested 24 h after exposure and seeded. Cells were fixed after 2h and immunostained to detect SiglecF,
505 CD11b, and M-CSF. Plot shows mean M-CSF signal intensities of individual ApoE⁺CD11b⁺ AMs (n=3 mice per
506 condition, two independent experiments). (H) Quantification of M-CSF protein levels in the BALF one day after
507 β -glucan exposure in control or ApoE^{fllox}LysM^{Cre} mice (n=6 mice, two independent experiments) measured by
508 ELISA. (I) BALF of PBS or β -glucan stimulated control or ApoE^{fllox}LysM^{Cre} mice was harvested three days after
509 exposure, seeded and fixed after 2 h. TUNEL staining was performed, followed by conventional
510 immunofluorescence to detect SiglecF and CD11b. Plot shows mean TUNEL signal intensities of individual

511 ApoE⁺CD11b⁺ AM (n=3 mice per condition, two independent experiments). (J) Absolute numbers of
512 ApoE⁺CD11b⁺ AM in the BALF of WT mice seven days after intranasal β -glucan treatment together with 500 μ g
513 of CSF-1R antibody or the respective isotype control and follow-up treatment 12 h and 3 days later (n=8-9 mice,
514 two independent experiments). Data are depicted as mean \pm SD, (A, B, G-I) ordinary one-way ANOVA with
515 Tukey's multiple comparisons, (D, F) Two-tailed Mann-Whitney test, (J) unpaired two-tailed student's *t*-test.

516

517 **References**

- 518 1. Kopf, M., Schneider, C., and Nobs, S.P. (2014). The development and function of lung-resident
519 macrophages and dendritic cells. *Nat Immunol* *16*, 36-44. 10.1038/ni.3052.
- 520 2. Divangahi, M., Aaby, P., Khader, S.A., Barreiro, L.B., Bekkering, S., Chavakis, T., van Crevel, R.,
521 Curtis, N., DiNardo, A.R., Dominguez-Andres, J., et al. (2021). Trained immunity, tolerance, priming
522 and differentiation: distinct immunological processes. *Nat Immunol* *22*, 2-6. 10.1038/s41590-020-
523 00845-6.
- 524 3. Shah, A., and Panjabi, C. (2014). Allergic aspergillosis of the respiratory tract. *European Respiratory*
525 *Review* *23*, 8-29. 10.1183/09059180.00007413.
- 526 4. Quintin, J., Saeed, S., Martens, J.H.A., Giamarellos-Bourboulis, E.J., Ifrim, D.C., Logie, C., Jacobs, L.,
527 Jansen, T., Kullberg, B.-J., Wijmenga, C., et al. (2012). *Candida albicans* Infection Affords Protection
528 against Reinfection via Functional Reprogramming of Monocytes. *Cell Host Microbe* *12*, 223-232.
529 10.1016/j.chom.2012.06.006.
- 530 5. Saeed, S., Quintin, J., Kerstens, H.H.D., Rao, N.A., Aghajani-refah, A., Matarese, F., Cheng, S.-C.,
531 Ratter, J., Berentsen, K., van der Ent, M.A., et al. (2014). Epigenetic programming of monocyte-to-
532 macrophage differentiation and trained innate immunity. *Science* *345*, 1251086.
533 10.1126/science.1251086.
- 534 6. Arts, R.J.W., Joosten, L.A.B., and Netea, M.G. (2016). Immunometabolic circuits in trained immunity.
535 *Seminars in Immunology* *28*, 425-430. 10.1016/j.smim.2016.09.002.
- 536 7. Arts, R.J.W., Novakovic, B., Ter Horst, R., Carvalho, A., Bekkering, S., Lachmandas, E., Rodrigues, F.,
537 Silvestre, R., Cheng, S.-C., Wang, S.-Y., et al. (2016). Glutaminolysis and Fumarate Accumulation
538 Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. *Cell metabolism* *24*, 807-
539 819. 10.1016/j.cmet.2016.10.008.
- 540 8. Bekkering, S., Arts, R.J.W., Novakovic, B., Kourtzelis, I., van der Heijden, C.D.C.C., Li, Y., Popa, C.D.,
541 Ter Horst, R., van Tuijl, J., Netea-Maier, R.T., et al. (2018). Metabolic Induction of Trained Immunity
542 through the Mevalonate Pathway. *Cell* *172*, 135-146.e139. 10.1016/j.cell.2017.11.025.
- 543 9. Cirovic, B., de Bree, L.C.J., Groh, L., Blok, B.A., Chan, J., van der Velden, W., Bremmers, M.E.J., van
544 Crevel, R., Handler, K., Picelli, S., et al. (2020). BCG Vaccination in Humans Elicits Trained Immunity
545 via the Hematopoietic Progenitor Compartment. *Cell Host Microbe* *28*, 322-334 e325.
546 10.1016/j.chom.2020.05.014.
- 547 10. Hussell, T., and Bell, T.J. (2014). Alveolar macrophages: plasticity in a tissue-specific context. *Nat Rev*
548 *Immunol* *14*, 81-93. 10.1038/nri3600.
- 549 11. Brown, G.D. (2005). Dectin-1: a signalling non-TLR pattern-recognition receptor. *Nat Rev Immunol* *6*,
550 33-43. 10.1038/nri1745.
- 551 12. Vornholz, L., and Ruland, J. (2020). Physiological and Pathological Functions of CARD9 Signaling in
552 the Innate Immune System. *Curr Top Microbiol Immunol* *429*, 177-203. 10.1007/82_2020_211.
- 553 13. Gross, O., Gewies, A., Finger, K., Schafer, M., Sparwasser, T., Peschel, C., Forster, I., and Ruland, J.
554 (2006). Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. *Nature* *442*, 651-
555 656. 10.1038/nature04926.
- 556 14. Williams, M., De Kleer, I., Henri, S., Post, S., Vanhoutte, L., De Prijck, S., Deswarte, K., Malissen, B.,
557 Hammad, H., and Lambrecht, B.N. (2013). Alveolar macrophages develop from fetal monocytes that
558 differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med* *210*, 1977-1992.
559 10.1084/jem.20131199.
- 560 15. Schneider, C., Nobs, S.P., Kurrer, M., Rehrauer, H., Thiele, C., and Kopf, M. (2014). Induction of the
561 nuclear receptor PPAR- γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes
562 into alveolar macrophages. *Nat Immunol* *15*, 1026-1037. 10.1038/ni.3005.

- 563 16. Aegerter, H., Kulikauskaite, J., Crotta, S., Patel, H., Kelly, G., Hessel, E.M., Mack, M., Beinke, S., and
564 Wack, A. (2020). Influenza-induced monocyte-derived alveolar macrophages confer prolonged
565 antibacterial protection. *Nature Immunology* *21*, 145-157. 10.1038/s41590-019-0568-x.
- 566 17. Gibbings, S.L., Thomas, S.M., Atif, S.M., McCubbrey, A.L., Desch, A.N., Danhorn, T., Leach, S.M.,
567 Bratton, D.L., Henson, P.M., Janssen, W.J., and Jakubzick, C.V. (2017). Three Unique Interstitial
568 Macrophages in the Murine Lung at Steady State. *American journal of respiratory cell and molecular
569 biology* *57*, 66-76. 10.1165/rcmb.2016-0361OC.
- 570 18. Machiels, B., Douarcy, M., Xiao, X., Javaux, J., Mesnil, C., Sabatel, C., Desmecht, D., Lallemand, F.,
571 Martinive, P., Hammad, H., et al. (2017). A gammaherpesvirus provides protection against allergic
572 asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes. *Nat
573 Immunol* *153*, 256. 10.1038/ni.3857.
- 574 19. Yao, Y., Jeyanathan, M., Haddadi, S., Barra, N.G., Vaseghi-Shanjani, M., Damjanovic, D., Lai, R.,
575 Afkhami, S., Chen, Y., Dvorkin-Gheva, A., et al. (2018). Induction of Autonomous Memory Alveolar
576 Macrophages Requires T Cell Help and Is Critical to Trained Immunity. *Cell* *175*, 1634-1650.e1617.
577 10.1016/j.cell.2018.09.042.
- 578 20. Park, Y., Ahn, C., and Kim, T.H. (2021). Occupational and environmental risk factors of idiopathic
579 pulmonary fibrosis: a systematic review and meta-analyses. *Sci Rep* *11*, 4318. 10.1038/s41598-021-
580 81591-z.
- 581 21. Rabe, K.F., and Watz, H. (2017). Chronic obstructive pulmonary disease. *Lancet (London, England)*
582 *389*, 1931-1940. 10.1016/S0140-6736(17)31222-9.
- 583 22. Lloyd, C.M., and Marsland, B.J. (2017). Lung Homeostasis: Influence of Age, Microbes, and the
584 Immune System. *46*, 549-561. 10.1016/j.immuni.2017.04.005.
- 585 23. Kaur, M., Bell, T., Salek-Ardakani, S., and Hussell, T. (2015). Macrophage adaptation in airway
586 inflammatory resolution. *European respiratory review : an official journal of the European Respiratory
587 Society* *24*, 510-515. 10.1183/16000617.0030-2015.
- 588 24. Murdoch, J.R., and Lloyd, C.M. (2010). Chronic inflammation and asthma. *Mutation research* *690*, 24-
589 39. 10.1016/j.mrfmmm.2009.09.005.
- 590 25. Rathnayake, C.M., Metwali, N., Jayarathne, T., Kettler, J., Huang, Y., Thorne, P.S., O'Shaughnessy,
591 P.T., and Stone, E.A. (2017). Influence of rain on the abundance of bioaerosols in fine and coarse
592 particles. *Atmos. Chem. Phys.* *17*, 2459-2475. 10.5194/acp-17-2459-2017.
- 593 26. Yu, X., Buttgereit, A., Lelios, I., Utz, S.G., Cansever, D., Becher, B., and Greter, M. (2017). The
594 Cytokine TGF- β ; Promotes the Development and Homeostasis of Alveolar Macrophages. 1-
595 15. 10.1016/j.immuni.2017.10.007.
- 596 27. Gautier, E.L., Shay, T., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K.G., Gordonov,
597 S., Mazloom, A.R., et al. (2012). Gene-expression profiles and transcriptional regulatory pathways that
598 underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* *13*, 1118-1128.
599 10.1038/ni.2419.
- 600 28. Cohen, M., Giladi, A., Gorki, A.-D., Solodkin, D.G., Zada, M., Hladik, A., Miklosi, A., Salame, T.M.,
601 Halpern, K.B., David, E., et al. (2018). Lung Single-Cell Signaling Interaction Map Reveals Basophil
602 Role in Macrophage Imprinting. *Cell* *175*, 1031-1044.e1018. 10.1016/j.cell.2018.09.009.
- 603 29. Jaitin, D.A., Adlung, L., Thaïss, C.A., Weiner, A., Li, B., Descamps, H., Lundgren, P., Blériot, C., Liu,
604 Z., Deczkowska, A., et al. (2019). Lipid-Associated Macrophages Control Metabolic Homeostasis in a
605 Trem2-Dependent Manner. *Cell* *178*, 686-698.e614. 10.1016/j.cell.2019.05.054.
- 606 30. Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T.K.,
607 David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017). A Unique Microglia Type Associated
608 with Restricting Development of Alzheimer's Disease. *Cell* *169*, 1276-1290.e1217.
609 10.1016/j.cell.2017.05.018.
- 610 31. McCubbrey, A.L., Barthel, L., Mohning, M.P., Redente, E.F., Mould, K.J., Thomas, S.M., Leach, S.M.,
611 Danhorn, T., Gibbings, S.L., Jakubzick, C.V., et al. (2018). Deletion of c-FLIP from CD11bhi
612 Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis. *American journal of
613 respiratory cell and molecular biology* *58*, 66-78. 10.1165/rcmb.2017-0154OC.
- 614 32. Halstead, E.S., Umstead, T.M., Davies, M.L., Kawasawa, Y.I., Silveyra, P., Howyrlak, J., Yang, L., Guo,
615 W., Hu, S., Hewage, E.K., and Chronos, Z.C. (2018). GM-CSF overexpression after influenza a virus
616 infection prevents mortality and moderates M1-like airway monocyte/macrophage polarization.
617 *Respiratory Research* *19*, 3. 10.1186/s12931-017-0708-5.
- 618 33. Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vazquez, G., Black, S., and Nolan,
619 G.P. (2018). Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. *Cell*
620 *174*, 968-981.e915. 10.1016/j.cell.2018.07.010.
- 621 34. Mould, K.J., Barthel, L., Mohning, M.P., Thomas, S.M., McCubbrey, A.L., Danhorn, T., Leach, S.M.,
622 Fingerlin, T.E., O'Connor, B.P., Reisz, J.A., et al. (2017). Cell Origin Dictates Programming of

- 623 Resident Versus Recruited Macrophages During Acute Lung Injury. *American journal of respiratory cell*
624 *and molecular biology*. 10.1165/remb.2017-0061OC.
- 625 35. Serbina, N.V., and Pamer, E.G. (2006). Monocyte emigration from bone marrow during bacterial
626 infection requires signals mediated by chemokine receptor CCR2. *Nat Immunol* 7, 311-317.
627 10.1038/ni1309.
- 628 36. Wang, Y.T., Trzeciak, A.J., Rojas, W.S., Saavedra, P., Chen, Y.T., Chirayil, R., Etchegaray, J.I., Lucas,
629 C.D., Puleston, D.J., Keshari, K.R., and Perry, J.S.A. (2023). Metabolic adaptation supports enhanced
630 macrophage efferocytosis in limited-oxygen environments. *Cell Metab* 35, 316-331 e316.
631 10.1016/j.cmet.2022.12.005.
- 632 37. Schilperoord, M., Ngai, D., Katerelos, M., Power, D.A., and Tabas, I. (2023). PFKFB2-mediated
633 glycolysis promotes lactate-driven continual efferocytosis by macrophages. *Nat Metab* 5, 431-444.
634 10.1038/s42255-023-00736-8.
- 635 38. Ataide, M.A., Manin, G.Z., Oliveira, S.S., Guerra, R.O., and Zamboni, D.S. (2023). Inflammasome
636 activation and CCR2-mediated monocyte-derived dendritic cell recruitment restrict *Legionella*
637 *pneumophila* infection. *Eur J Immunol* 53, e2249985. 10.1002/eji.202249985.
- 638 39. Vazquez-Armendariz, A.I., Heiner, M., El Agha, E., Salwig, I., Hoek, A., Hessler, M.C., Shalashova, I.,
639 Shrestha, A., Carraro, G., Mengel, J.P., et al. (2020). Multilineage murine stem cells generate complex
640 organoids to model distal lung development and disease. *EMBO J* 39, e103476.
641 10.15252/embj.2019103476.
- 642 40. Fesel, P.H., and Zuccaro, A. (2016). β -glucan: Crucial component of the fungal cell wall and elusive
643 MAMP in plants. *Fungal genetics and biology : FG & B* 90, 53-60. 10.1016/j.fgb.2015.12.004.
- 644 41. Kalia, N., Singh, J., and Kaur, M. (2021). The role of dectin-1 in health and disease. *Immunobiology*
645 226, 152071. 10.1016/j.imbio.2021.152071.
- 646 42. Taylor, P.R., Tsoni, S.V., Willment, J.A., Dennehy, K.M., Rosas, M., Findon, H., Haynes, K., Steele, C.,
647 Botto, M., Gordon, S., and Brown, G.D. (2007). Dectin-1 is required for beta-glucan recognition and
648 control of fungal infection. *Nat Immunol* 8, 31-38. 10.1038/ni1408.
- 649 43. Deerhake, M.E., Danzaki, K., Inoue, M., Cardakli, E.D., Nonaka, T., Aggarwal, N., Barclay, W.E., Ji,
650 R.R., and Shinohara, M.L. (2021). Dectin-1 limits autoimmune neuroinflammation and promotes
651 myeloid cell-astrocyte crosstalk via Card9-independent expression of Oncostatin M. *Immunity* 54, 484-
652 498 e488. 10.1016/j.immuni.2021.01.004.
- 653 44. Kemp, S.B., Carpenter, E.S., Steele, N.G., Donahue, K.L., Nwosu, Z.C., Pacheco, A., Velez-Delgado,
654 A., Menjivar, R.E., Lima, F., The, S., et al. (2021). Apolipoprotein E Promotes Immune Suppression in
655 Pancreatic Cancer through NF-kappaB-Mediated Production of CXCL1. *Cancer Res* 81, 4305-4318.
656 10.1158/0008-5472.CAN-20-3929.
- 657 45. Dove, D.E., Linton, M.F., and Fazio, S. (2005). ApoE-mediated cholesterol efflux from macrophages:
658 separation of autocrine and paracrine effects. *Am J Physiol Cell Physiol* 288, C586-592.
659 10.1152/ajpcell.00210.2004.
- 660 46. Blanchard, J.W., Akay, L.A., Davila-Velderrain, J., von Maydell, D., Mathys, H., Davidson, S.M.,
661 Effenberger, A., Chen, C.Y., Maner-Smith, K., Hajjar, I., et al. (2022). APOE4 impairs myelination via
662 cholesterol dysregulation in oligodendrocytes. *Nature* 611, 769-779. 10.1038/s41586-022-05439-w.
- 663 47. Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei,
664 A.S., Ricci, B., et al. (2020). TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing
665 Anti-PD-1 Immunotherapy. *Cell*. 10.1016/j.cell.2020.07.013.
- 666 48. Misharin, A.V., Morales-Nebreda, L., Reyfman, P.A., Cuda, C.M., Walter, J.M., McQuattie-Pimentel,
667 A.C., Chen, C.-I., Anekalla, K.R., Joshi, N., Williams, K.J.N., et al. (2017). Monocyte-derived alveolar
668 macrophages drive lung fibrosis and persist in the lung over the life span. *J Exp Med* 214, 2387-2404.
669 10.1084/jem.20162152.
- 670 49. Li, F., Piattini, F., Pohlmeier, L., Feng, Q., Rehrauer, H., and Kopf, M. (2022). Monocyte-derived
671 alveolar macrophages autonomously determine severe outcome of respiratory viral infection. *Sci*
672 *Immunol* 7, eabj5761. 10.1126/sciimmunol.abj5761.
- 673 50. Idol, R.A., Bhattacharya, S., Huang, G., Song, Z., Huttenlocher, A., Keller, N.P., and Dinauer, M.C.
674 (2022). Neutrophil and Macrophage NADPH Oxidase 2 Differentially Control Responses to
675 Inflammation and to *Aspergillus fumigatus* in Mice. *J Immunol* 209, 1960-1972.
676 10.4049/jimmunol.2200543.
- 677 51. Hohl, T.M., Rivera, A., Lipuma, L., Gallegos, A., Shi, C., Mack, M., and Pamer, E.G. (2009).
678 Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection.
679 *Cell Host Microbe* 6, 470-481. 10.1016/j.chom.2009.10.007.
- 680 52. Zahalka, S., Starkl, P., Watzenboeck, M.L., Farhat, A., Radhouani, M., Deckert, F., Hladik, A., Lakovits,
681 K., Oberndorfer, F., Lassnig, C., et al. (2022). Trained immunity of alveolar macrophages requires
682 metabolic rewiring and type 1 interferon signaling. *Mucosal Immunol*. 10.1038/s41385-022-00528-5.

- 683 53. Serbina, N.V., Cherny, M., Shi, C., Bleau, S.A., Collins, N.H., Young, J.W., and Pamer, E.G. (2009).
684 Distinct responses of human monocyte subsets to *Aspergillus fumigatus* conidia. *J Immunol* *183*, 2678-
685 2687. 10.4049/jimmunol.0803398.
- 686 54. Loeffler, J., Haddad, Z., Bonin, M., Romeike, N., Mezger, M., Schumacher, U., Kapp, M., Gebhardt, F.,
687 Grigoleit, G.U., Stevanovic, S., et al. (2009). Interaction analyses of human monocytes co-cultured with
688 different forms of *Aspergillus fumigatus*. *J Med Microbiol* *58*, 49-58. 10.1099/jmm.0.003293-0.
- 689 55. Novakovic, B., Habibi, E., Wang, S.-Y., Arts, R.J.W., Davar, R., Megchelenbrink, W., Kim, B.,
690 Kuznetsova, T., Kox, M., Zwaag, J., et al. (2016). β -Glucan Reverses the Epigenetic State of LPS-
691 Induced Immunological Tolerance. *Cell* *167*, 1354-1368.e1314. 10.1016/j.cell.2016.09.034.
- 692 56. Mitroulis, I., Ruppova, K., Wang, B., Chen, L.-S., Grzybek, M., Grinenko, T., Eugster, A., Troullinaki,
693 M., Palladini, A., Kourtzelis, I., et al. (2018). Modulation of Myelopoiesis Progenitors Is an Integral
694 Component of Trained Immunity. *Cell* *172*, 147-161.e112. 10.1016/j.cell.2017.11.034.
- 695 57. Kalafati, L., Kourtzelis, I., Schulte-Schrepping, J., Li, X., Hatzioannou, A., Grinenko, T., Hagag, E.,
696 Sinha, A., Has, C., Dietz, S., et al. (2020). Innate Immune Training of Granulopoiesis Promotes Anti-
697 tumor Activity. *Cell* *183*, 771-785 e712. 10.1016/j.cell.2020.09.058.
- 698 58. Li, X., Wang, H., Yu, X., Saha, G., Kalafati, L., Ioannidis, C., Mitroulis, I., Netea, M.G., Chavakis, T.,
699 and Hajishengallis, G. (2022). Maladaptive innate immune training of myelopoiesis links inflammatory
700 comorbidities. *Cell* *185*, 1709-1727 e1718. 10.1016/j.cell.2022.03.043.
- 701 59. Murphy, A.J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.L., Wang, M., Sanson, M.,
702 Abramowicz, S., Welch, C., et al. (2011). ApoE regulates hematopoietic stem cell proliferation,
703 monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. *J Clin Invest* *121*, 4138-
704 4149. 10.1172/JCI57559.
- 705 60. Christ, A., Günther, P., Lauterbach, M.A.R., Duewell, P., Biswas, D., Pelka, K., Scholz, C.J., Oosting,
706 M., Haendler, K., Baßler, K., et al. (2018). Western Diet Triggers NLRP3-Dependent Innate Immune
707 Reprogramming. *Cell* *172*, 162-175.e114. 10.1016/j.cell.2017.12.013.
- 708

709 **Methods**

710 **Animal studies and mouse models**

711 All mice used in this study were bred in the animal facility of the LIMES Institute, University of Bonn, Germany
712 or Center for Translational Cancer Research, Klinikum rechts der Isar, Technical University of Munich, Germany.
713 Animals were housed in IVC mice cages under conventional conditions (12 h/12 h light/dark cycle, 22°C), with
714 ad libitum access to food and water. All experiments were performed using C57BL/6J (WT) mice, which also
715 served as controls for CCR2, Dectin-1, CARD9 knockout mice. For ApoE^{flox}LysM^{Cre/+} mice, Cre-negative
716 ApoE^{flox}LysM^{+/+} littermates were used as controls. Eight to twelve weeks old male mice were used for
717 experiments. All experiments were approved by government of North Rhine-Westphalia (84-02.04.2017.A347,
718 81-02.04.2020.A454).

719

720 **Intranasal stimulation**

721 Mice were anesthetized by intraperitoneal injection of ketamine/xylazine and intranasally inoculated with
722 endotoxin-free 1x PBS (EMD Millipore) or 200 µg β-glucan from *Candida albicans*. BALF was collected one,
723 three, seven, 14 or 21 days after inoculation. For cell analysis, the lung was flushed 3x with 1 ml cold 1x PBS
724 with 10 mM EDTA. Afterwards, the fluid was centrifuged for 5 min at 365 g at 4°C and the supernatant was
725 discarded. For cytokine and chemokine assessment, the lung was flushed 3x with the same 1 ml of cold 1x PBS
726 with 10 mM EDTA. Afterwards, the supernatant without cells was frozen in liquid nitrogen until analysis.
727 Supernatants were thawed on ice and centrifuged for 5 min at 10 000 rpm at 4°C to remove debris. M-CSF (R&D
728 Systems) and ApoE (Abcam) protein levels were measured by ELISA according to manufacturer's protocols.

729

730 **Macrophage transfer**

731 C57BL/6J CD45.2 wildtype donor mice were intranasally stimulated with PBS or β-glucan as described above.
732 At day five, BAL fluid was harvested and cells of the same condition were pooled. After centrifugation, the
733 supernatant was discarded and cells were resuspended in LPS-free 1x PBS. Afterwards, 2x10⁵ donor cells in the
734 volume of 35 µl were intratracheally transferred into CD45.1 recipient mice. BALF was harvested 48 h post
735 transfer and either analyzed by flow cytometry or used for *ex vivo* restimulation with LPS (see below).

736

737 ***In vivo* CSF-1 receptor blockade**

738 Before *in vivo* application, the amount of the anti-CSF-1R or the isotype control antibody was calculated per
739 cohort. To reduce the application volume, a Concentrator Plus vacuum centrifuge (Eppendorf) was used in V-AQ
740 mode to evaporate excess liquid to yield a final product in 1/4 of the starting volume. C57BL/6J wildtype mice
741 were intranasally stimulated with β -glucan mixed with 500 μ g anti-CSF-1R antibody (BioLegend) or 500 μ g
742 isotype control (BioLegend). 12 h and three days after the initial treatment, intranasal application of 500 μ g anti-
743 CSF-1R antibody or the respective isotype control was repeated before analysis at day seven.

744

745 **Pulmonary fibrosis and *Legionella pneumophila* infection**

746 Mice were intranasally stimulated with β -glucan or PBS seven days before induction of pulmonary fibrosis or
747 infection by *Legionella pneumophila*. For fibrosis induction, *Streptomyces verticillus* bleomycin (Sigma-Aldrich,
748 0.75 mg/kg body weight) was administered by intranasal installation. Body weight and health status were scored
749 on a daily basis. Analysis was performed three or 14 days after bleomycin application. For bacterial infections,
750 intratracheal application of *Legionella pneumophila* (5×10^6 CFU/mouse) was performed and mice were sacrificed
751 two days after induction. For bacterial load determination, BALF supernatant was plated in duplicates on CYE-
752 plates and grown for 3-4 days at 37°C in a non-CO₂ incubator.

753

754 **Bone marrow Chimeras**

755 BM chimeras were generated by multiple intraperitoneal busulfan (Sigma-Aldrich) injections or irradiation of
756 recipient mice with 10 Gy. Afterwards, 5×10^6 (busulfan-treated mice) or 1.5×10^6 (irradiated mice) freshly
757 isolated BM cells from the donor animals were intravenously injected into the recipients. Peripheral blood
758 chimerism was assessed 28 days after reconstitution by flow cytometry. BM chimeras were used in experiments
759 after eight – twelve weeks of reconstitution.

760

761 **Flow cytometry and cell sorting**

762 For flow cytometry, cells of the broncho-alveolar space were harvested by flushing the lungs with 3x 1 ml ice
763 cold 1x PBS containing 10 mM EDTA. After centrifugation with 365 g for 5 min at 4°C, cell pellets were
764 resuspended in antibody mix and stained for 35 min at 4°C. After washing with FACS buffer (1x PBS, 2 mM
765 EDTA, 0.5% BSA (SERVA)), life/death stain was performed using DRAQ7 (BioLegend, 1:1000 in FACS buffer)
766 for 5 min at RT. Red blood cell lysis was performed only if necessary. For the lung tissue, the more segmented
767 lobe was minced and enzymatically digested for 45 min at 37°C in HBSS (PAN Biotech) supplemented with 10%

768 FCS (Sigma-Aldrich), 0.2 mg/ml collagenase IV (Sigma-Aldrich) and 0.05 mg/ml DNase I (Sigma-Aldrich).
769 Afterwards, the tissue pieces were homogenized with a 19G syringe and filtered through a 70 µm strainer. Red
770 blood cell lysis was performed once for 5 min at RT prior to life/death stain and acquisition. In case of blood
771 analysis, blood was collected in 1x PBS with 10 mM EDTA and stained in antibody mix for 35 min at 4°C. Red
772 blood cell lysis was performed twice for 5 min at RT prior to life/death stain and acquisition. For BM cells, femur
773 and tibia were flushed with 1x PBS, stained with antibody mix for 1 h and red blood cell lysis and life/death stain
774 were subsequently performed. Cells were washed and resuspended in FACS buffer and recorded using FACS
775 Symphony A5 (Becton Dickinson). FACS data were analyzed using FlowJo v10.8.1 (Becton Dickinson).
776 Cell sorting was performed using an ARIA III (Becton Dickinson) instrument. Briefly, cells from the lung lavage
777 were antibody stained followed by life/death stain. Cell sorting was performed using a 100 µm nozzle into cooled
778 1.5 ml reaction tubes containing FACS buffer.

779 Monoclonal anti-mouse antibodies, including anti-CD45R (clone RA3-6B2, BioLegend, 1:400), anti-CD117
780 (clone 2B8, BioLegend, 1:200), anti-CD11b (clone M1/70, BioLegend, 1:200), anti-CD11c (clone N418,
781 BioLegend, 1:200), anti-CD11c (clone N418, BioLegend, 1:200), anti-CD135 (clone A2F10, BD Bioscience,
782 1:200), anti-CD192 (clone SA203G11, BioLegend or clone 475301, BD Bioscience, 1:200), anti-CD19 (clone
783 6D5, BioLegend, 1:200), anti-CD150 (clone 475301, BioLegend, 1:200), anti- CD3 (clone 17A2, BioLegend,
784 1:200), anti-CD131 (clone JORO 50, BD Bioscience, 1:200), anti-CD45 (clone I3/2.3, BioLegend or 30-F11,
785 BioLegend/BD Bioscience, 1:200), anti-CD45.1 (clone A20, BD Bioscience, 1:200), anti-CD45.2 (clone 104, BD
786 Bioscience, 1:200), anti-CD16/32 (clone 2.4G2, BDHorizon or clone 93, BioLegend, 1:100), anti-CD206 (clone
787 C068C2, BioLegend, 1:200), anti-CD48 (clone HM48-1, BioLegend, 1:100), anti-CD90 (clone 53-2.1,
788 BioLegend, 1:200), anti-CD64, (clone X54-5/7.1, BioLegend, 1:100), anti-CX3CR1 (clone SA011F11,
789 BioLegend, 1:100), anti-F4/80 (clone BM8, BioLegend, 1:100), anti-IL-6 (clone MP5-20F3, BD Biosciences,
790 1:100), anti-Ly6C (clone HK1.4, BioLegend, 1:200), anti-Ly6G (clone 1A8, BioLegend/BD Bioscience, 1:200),
791 anti-MERTK (clone 2B10C42, BioLegend, 1:200), anti-MHC2 (clone M5/114.15.2 , BioLegend/BD Bioscience,
792 1:200), anti-NK-1.1 (clone PK136, BioLegend, 1:200), anti-Ly-6A/E (clone D7, Thermo Fisher Scientific, 1:200),
793 anti-Siglec F (clone E50-2440, BD Biosciences, 1:200), anti-mouse TCR beta chain (clone H57-597, BioLegend,
794 1:400), anti-TER-119, (clone TER-119, BioLegend, 1:200), anti-CD34 (clone SA376A4, BioLegend, 1:100),
795 anti-CD335 (clone 29A1.4, BioLegend, 1:200), anti-CD115 (clone AFS98, BioLegend or clone T38-320, BD
796 Bioscience, 1:100), anti-CD24 (clone M1/69, BioLegend/BD Bioscience, 1:100), anti-Sca-1 (clone D7,
797 BioLegend, 1:100), anti-CD43 (clone S7, BD Bioscience, 1:200) were used for flow cytometry or cell sorting.

798

799 **PrimeFlow RNA detection by flow cytometry**

800 BALFs of three stimulated wildtype mice were pooled, centrifuged at 365 g for 5 min at 4°C and resuspended in
801 antibody mix for surface staining. Samples were transferred to 1.5 ml microcentrifuge tubes provided by the
802 PrimeFlow RNA Assay Kit (ThermoFisher Scientific) and stained for 35 min at 4° C. Afterwards, life/death
803 staining was performed using Zombie NIR Fixable Viability dye (1:1000 in PBS, BioLegend) for 10 min at RT.
804 In the further steps, samples were handled according to manufacturer's instructions.

805

806 ***Ex vivo* stimulation and assessment of cytokine production**

807 BALF of stimulated mice was collected, centrifuged at 365 g for 5 min at 4°C and resuspended in 1 ml RPMI1640
808 (PAN Biotech) supplemented with 10% FCS (Sigma-Aldrich), 2 mM GlutaMAX (Gibco), 1% MEM non-essential
809 amino acids (Sigma Aldrich), 1 mM Na-Pyruvate (Gibco), 50 U/ml Pen-Strep (Gibco) and 0.1% β-
810 Mercaptoethanol. Cells were counted and seeded with 0.2 x10⁵ cells per well. After 2 h resting in 500 µl medium
811 at 37°C and 5% CO₂, medium was exchanged to wash away non-adherent cells. Remaining macrophages were
812 subsequently stimulated with 10 ng/ml LPS (Sigma-Aldrich) in a final volume of 500 µl. For intracellular cytokine
813 stain, cells were restimulated for 4 h, then 2.5 µg Brefeldin A (BioLegend) and 2 nM Monensin (BioLegend) were
814 added to each well and incubated for further 2 h. Cells were harvested in 1x PBS using a cell scraper followed by
815 staining of surface markers by antibodies for 30 min at 4°C. Cells were washed and stained with Zombie NIR
816 fixable viability dye (1:1000 in PBS, BioLegend) for 15 min. Afterwards, cells were permeabilized using the
817 Cytotfix/Cytoperm kit (Becton Dickinson, adapted from manufacturer's protocol). In brief, cells were resuspended
818 in 200 µl Cytotfix/Cytoperm solution per tube and incubated for 20 min at 4°C. Cells were washed twice with
819 Perm/Wash and intracellularly stained by 100 µl Perm/Wash containing IL-6 (MP5-20F3; 1:100) antibody or the
820 corresponding isotype control for 30 min at 4°C. Cells were washed twice with Perm/Wash and resuspended in
821 1x PBS before acquisition. For cytokine assessment from the supernatant, cell culture supernatant was harvested
822 24 h after LPS and snap frozen for further analysis. Supernatants were thawed on ice and centrifuged for 5 min at
823 10 000 rpm at 4°C to remove debris. IL-6 (ThermoFisher) protein levels were measured by ELISA. For multiplex
824 cytokine and chemokine analysis, a customized 18-plex Procartaplex kit (ThermoFisher) was used according to
825 manufacturer's protocols and run on Luminex FLEXMAP 3D (ThermoFisher) device.

826

827

828 ***In vitro* phagocytosis assay**

829 BALF cells of PBS or β -glucan inoculated mice were seeded with 0.2×10^5 cells per well in a 96 well plate and
830 selected by adherence as before. Medium was exchanged to 100 μ l medium or 100 μ l medium containing 2.5 μ g
831 pHrodo *S. aureus* bioparticles (Sartorius) per well. Phagocytosis was monitored every 10 min for 7 h in total using
832 the microscopy-based approach of the Incucyte instrument (Sartorius). Analysis was performed using the Incucyte
833 basic analyzer software in standard mode with two channels (phase and orange).

834

835 **Extracellular flux analysis**

836 BALF of two mice was pooled and $0.5 - 1 \times 10^5$ cells were plated in a 96 well Seahorse plate (Agilent) in Seahorse
837 XF base medium (Agilent) supplemented with 5% L-Glutamine (Sigma-Aldrich), 10% FCS (Sigma-Aldrich) and
838 50 U/ml Pen/Strep (Gibco) for 2 h at 37°C and 5% CO₂. Before acquisition, cells were washed and incubated in
839 FCS and Glucose free Seahorse XF base medium with 5% L-Glutamine (Sigma-Aldrich) and 50 U/ml Pen/Strep
840 (Gibco). During the run, 100 mM Glucose (Sigma-Aldrich) solution was injected into port A leading to a final
841 glucose concentration of 10 mM per well. This was followed by injection of 10 μ M Oligomycin A (Sigma-
842 Aldrich, final concentration 1 μ M) solution and 500 mM 2-Desoxyglucose (Sigma-Aldrich, final concentration
843 50 mM). Glycolysis, glycolytic capacity and glycolytic reserve were calculated using the Agilent Wave software.
844 After the Seahorse assay, cell numbers per well were determined for normalization using the CyQUANT NF Cell
845 Quantification Assay (Thermo-Fisher) and a TECAN plate reader.

846

847 **Lung organoid generation, fibrosis induction by TGF- β and immunofluorescence staining**

848 Organoid cultures were prepared as previously described and cultured at 37°C with 5% CO₂ ³⁹. In brief, lung
849 single cell suspensions were prepared from adult wildtype mice and CD31⁺CD45⁺CD16/32⁺ cells were depleted
850 by antibody-coupled magnetic beads. From the CD31⁻CD45⁻CD16/32⁻ negative fraction, EpCAM^{high}CD24^{low}Sca-
851 1⁺ BASC and EpCAM⁻Sca-1⁺ rMC were isolated by FACS. 5×10^3 BASC and 1.8×10^4 rMC were pooled and
852 mixed with growth factor-reduced Matrigel (Corning) (1:1) and seeded on 12 mm cell culture inserts in a 24-well
853 plate. α -MEM medium (ThermoFisher) supplemented with 10% FCS (ThermoFisher), 50 U/ml Pen/Strep
854 (ThermoFisher), 1x Insulin-Transferrin-Selenium (ThermoFisher) and 2 μ g/ml heparin (Stemcell Technologies)
855 was added to the wells to obtain an air-liquid interface. For the co-culture, alveolar macrophages were obtained
856 from the BALF of wildtype mice seven days after PBS or β -glucan inoculation. Subsequently, 2.5×10^4 AM were
857 seeded on top of the Matrigel layer of the day 21 organoid cultures. 24 h later, the organoid-AM co-cultures were

858 treated with medium containing either PBS or 1.05 ng/ml TGF- β (Miltenyi Biotech) to induce fibrosis. After 48
859 h of TGF- β treatment, cultures were fixed in 4% PFA, permeabilized and blocked overnight with 1x PBS
860 containing 0.5% Triton-X-100 (ThermoScientific) and 5% donkey serum (PAN Biotech) (blocking buffer).
861 Primary and secondary antibodies were incubated overnight in blocking buffer. The samples were cleared by
862 glycerol-fructose clearing as recently described ¹.

863

864 **Histology**

865 Mice were anesthetized followed by trans-cardial perfusion with 10 ml ice cold 1xPBS containing 10 mM EDTA
866 using the lung-heart circulation. Lungs were removed and fixed in 4% PFA overnight at 4°C (for paraffin-
867 embedded tissue) or infiltrated with 1 ml 50% OCT (in 1xPBS), removed, and fixed for 6 h in 1.3% PFA at 4°C.
868 For paraffin sections lungs were dehydrated and paraffin embedded. For frozen sections, after fixation lungs were
869 dehydrated in 10, 20, and 30% sucrose (in 1x PBS) for 24 h at 4°C. After dehydration, the left lobe was separated
870 and embedded in OCT. Sections of 5 μ m were prepared for immunohistochemistry.

871

872 **Immunofluorescence and histology staining**

873 Coverslips containing frozen tissue sections were left drying on drierite beads for 5min and subsequently fixed
874 on ice-cold acetone for 10 min. Afterwards, sections were washed twice and permeabilized with 0.2% Triton X-
875 100 for 20min at RT. Afterwards, sections were washed twice with 1x PBS and photobleached as described before
876 ². Following photobleaching, sections were blocked in 3% BSA for 1 h at RT. After blocking, primary antibodies
877 were added and left incubating overnight at 4°C. Sections were then washed three times with 1x PBS and
878 secondary antibodies and nuclear staining were subsequently added and left incubating for 1 h at RT. Samples
879 were washed as before and coverslips were mounted using mounting medium. Fluorescently labeled primary
880 antibodies were added after washing the secondary antibodies and left incubating 2 h at RT. For
881 immunofluorescence of cultured cells no acetone fixation and photobleaching were performed.

882 Histological evaluation of lung fibrosis was performed by Picrosirius red and Masson's trichrome stainings of
883 two consecutive paraffin-embedded 5 μ m tissue sections as previously described ^{3,4}.

884

885 **Filipin, TUNEL, BODIPY-Cholesterol staining**

886 5-8x10⁴ BALF cells were seeded in complete RPMI medium in a 24-well plate containing sterile glass coverslips.
887 Cells were left adhering for 3 h at 37°C. For filipin and TUNEL stainings, cells were washed with 1x PBS and

888 subsequently fixed with 4% PFA for 30 min. For filipin staining, after washing away the fixative, cells were
889 incubated in 100 mM glycine for 10 min at RT, and subsequently blocked with 3% BSA supplemented with 50
890 $\mu\text{g/ml}$ filipin (Sigma-Aldrich) for 2 h at RT. Cells were washed three times with 1x PBS and immunostained as
891 indicated above, but DRAQ5 (ThermoFisher Scientific) was used as a counterstain. For TUNEL staining,
892 manufacturer's instructions were followed and immunofluorescence was performed after TUNEL (ThermoFisher
893 Scientific). For BODIPY-cholesterol staining, BALF cells were seeded in 8-well chamber slides, left as before,
894 and incubated overnight in complete RPMI1640 medium supplemented with 0.5 μM BODIPY-Cholesterol
895 (Biomol). Cells were washed three times with 1x PBS, fixed, permeabilized and immunostained as described
896 above.

897

898 **Imaging**

899 Images of the Picrosirius Red and Trichrome stainings were acquired using the OLYMPUS Slideview VS200
900 (Evident Corporation). Sections were analyzed at a 20-fold magnification. Images of immunofluorescence of
901 tissue sections and cultured cells were acquired using a Zeiss LSM 880 Airyscan system using a 60x oil immersion
902 objective (NA) with a z-spacing of 500 nm. Images were acquired using the 405, 488, 561 and 640 nm laser lines.
903 During acquisition, nuclei showing the prototypical shape of neutrophils or eosinophils were excluded.

904

905 **Image analysis**

906 To quantify signal intensities from different markers from individual BALF cells, images were analyzed with a
907 customized pipeline in CellProfiler. Briefly, Hoechst or DRAQ5 signals were used to segment the cells. A second
908 primary detection step was added to create a mask of all SiglecF⁺ objects. This mask was subsequently merged
909 onto the nuclei mask and only overlapping objects were further analyzed. A secondary object detection step was
910 incorporated to distinguish between ApoE⁺CD11b⁺ and CD11b⁻ cells and create a mask of alveolar macrophages.
911 Analysis of immunofluorescence of tissue sections was performed in QuPath⁵. Nuclear signals were used to
912 identify all objects using a radius of 2 μm . For each channel, an object classifier was created to set the detection
913 threshold based on the mean signal intensity. Subsequently, these classifiers were combined to identify alveolar
914 macrophages. Individual cell mean intensities were exported. To measure the area of fibrosis and the Ashcroft
915 score, scoring was performed in four different areas of each slide as previously described^{6,7}. Quantification of
916 fibrotic area from total tissue area was performed with ImageJ. The Ashcroft score was quantified using scores
917 ranging from 0 to 8 by two independent investigators, which were blinded to the treatments. To score fibrosis in

918 cultured organoids, images were imported into QuPath and the area of the organoid was annotated using DAPI as
919 a reference. A pixel classifier to detect SMA positive areas was trained using the control samples (i.e. untreated
920 and TGF- β treated). 5-10 exemplary regions of SMA and background spots were selected. The trained model was
921 applied to analyze all the images. The total SMA⁺ area of each organoid was quantified. To quantify the percentage
922 of co-localization and overlapping area of BODIPY-Cholesterol with cellular organelles, full z-stacks of single
923 ApoE⁺CD11b⁺ and CD11b⁻ AMs were uploaded to Fiji and analyzed using the JACoP plugin, as described before
924 ⁸. Thresholds were established using 5 randomly selected images from each condition and then applied in all the
925 images.

926

927 **CODEX multiplexed imaging and analysis**

928 Fresh frozen sections of the left lobe of the lung of 8-week *Ms4a3-cre*^{Rosa26^{TOMATO}} mouse seven days after
929 intranasal PBS or β -glucan were prepared and stained following manufacturer's instructions. Briefly, sections
930 were fixed in ice-cold acetone for 10 min. Afterwards, samples were rehydrated and permeabilized for 20 min
931 with 0.2% Triton-X100. Sections were photobleached twice for 1 h as indicated before ⁸. After photobleaching,
932 samples were equilibrated for 30 min in staining buffer (Akoya Biosciences), and subsequently stained with a 17-
933 plex CODEX antibody panel overnight at 4°C. After staining, samples were washed in staining buffer, fixed in
934 ice-cold methanol and washed. A final fixation step with BS3 crosslinker (Sigma Aldrich) was performed.
935 Specimens were stored in CODEX storage buffer (Akoya Biosciences) at 4°C for a maximum of one week before
936 imaging. BALF cells from wildtype mice were seeded on CODEX coverslips after harvesting seven days after
937 intranasal stimulation. 2 h after seeding, cells were fixed with 4% PFA for 20 min, washed, and stored in PBS at
938 4°C until CODEX staining. Except for the initial drying step, the same staining protocol and CODEX panel as for
939 the lung sections were used.

940 Antibody detection was performed in a multicycle experiment with the corresponding fluorescently-labeled
941 reporters, following manufacturer's instructions. Images were acquired with a Zeiss Axio Observer widefield
942 microscope (Carl Zeiss AG, Jena, Germany) using a 20x air objective (NA 0.85) and a z-spacing of 1.5 μ m. The
943 405, 488, 568, 647 nm fluorescent channels were used. After acquisition, images were exported using the CODEX
944 Instrument Manager (CIM, Akoya Biosciences) and processed with the CODEX Processor v1.7 (Akoya
945 Biosciences). Cells were segmented using DAPI signals and ATPase I membrane staining to define the cell
946 borders. Cell classification to detect alveolar macrophages and other MPs was performed in CODEX MAV
947 (Akoya Biosciences), following a similar gating scheme as the one used for flow cytometry.

948

949 **Preparation of Seq-Well arrays and libraries**

950 Seq-Well arrays and libraries were generated as previously described⁹. Briefly, arrays were generated by pouring
951 PDMS master mix into master molds and then functionalized by plasma treatment, washing with acetone,
952 incubation with 0.2% chitosan solution and subsequent incubation in PGA buffer under vacuum pressure. For
953 library generation, 1.1×10^5 barcoded mRNA-capture beads in Bead Loading Buffer were loaded onto the array.
954 $2-3 \times 10^4$ BALF cells in RPMI1640 medium (Gibco) with 10% FCS (Sigma-Aldrich) were loaded and rocked for
955 10 min. The loaded arrays were washed, sealed by polycarbonate membranes under mild vacuum, incubated for
956 30 min at 37°C in Agilent clamps (Agilent) and then incubated in a guanidinium-based lysis buffer for 20 min.
957 After incubation in hybridization buffer, the mRNA capture beads were washed from arrays and collected.
958 Reverse transcription was performed on the bead pellet using a Maxima Reverse Transcriptase reaction
959 (ThermoFisher) for 30 min at RT followed by 90 min incubation at 52°C before stopping the reaction with TE
960 buffer supplemented with 0.01% Tween-20. Excess primers were digested by exonuclease ExoI (New England
961 Biolabs). Beads were counted and the reverse transcribed cDNA libraries were amplified in a PCR reaction. After
962 PCR, $2-4 \times 10^4$ beads were pooled and cleaned using AMPure XP beads (Beckman Coulter). The library integrity
963 was assessed using a High Sensitivity D5000 assay (Agilent) for TapeStation 4200 (Agilent).

964

965 **Sequencing**

966 The cDNA libraries (1 ng) were tagmented with the prepared single-loaded Tn5 transposase mixed with pre-
967 annealed linker oligonucleotides and afterwards cleaned using MinElute PCR kit (Qiagen) following the
968 manufacturer's instructions. The Illumina indices (Illumina) were added to the tagmented product by PCR and
969 subsequently cleaned by AMPure XP beads (Beckman Coulter). The final library quality was assessed using a
970 High Sensitivity DNA5000 assay (Agilent) and quantified using the Qubit high-sensitivity dsDNA assay
971 (ThermoFisher). Seq-Well libraries were equimolarly pooled and clustered at 1.4 pM concentration with 10%
972 PhiX using High Output v2.1 chemistry (Illumina) on a NextSeq500 system (Illumina). Sequencing was
973 performed paired-end as followed: custom Drop-Seq Read 1 primer for 21 cycles, 8 cycles for the i7 index and
974 61 cycles for Read 2. Single-cell data were demultiplexed using bcl2fastq2 (v2.20) (Illumina). Fastq files were
975 loaded into a snakemake-based data pre-processing pipeline (version 0.31, available at
976 <https://github.com/Hoohm/dropSeqPipe>)¹⁰.

977

978 **scRNAseq data analysis**

979 Sequencing reads were mapped to the mouse reference genome mm10 using STAR alignment from the Drop-seq
980 pipeline (v2.0.0) as previously described ¹⁰. Next, we assess the quality of our libraries and excluded cells with
981 low quality (<500 genes per cell), doublets (>3000 genes per cell), or dead cells (>10% of mitochondrial content).
982 All genes expressed in less than five cells were filtered out.
983 Cell clustering analysis was performed using the Seurat package (v4.1.1) according to instructions ¹¹. In brief, the
984 expression data was log normalized with a scale factor of 10,000. After scaling, PCA was performed using the
985 top 2000 variable genes for a linear dimensional reduction. The first 10 PCA components were used to cluster
986 cells by the Louvain algorithm. To obtain an optimal cluster resolution, we set the resolution parameter in the
987 FindClusters function as 0.25 to generate 5 major clusters, which were visualized after non-linear dimensional
988 reduction with UMAP. Differentially expressed genes (DEGs) in each cluster were identified by using the default
989 Wilcoxon rank sum test in the FindAllMarkers function, and were defined with logfc.threshold >0.25 and min.pct
990 >0.25.

991

992 **Statistics**

993 Statistical analysis and comparison was performed using Prism 10 (GraphPad). Data are shown as mean ± SD.
994 Statistical significance was assessed by student's t-test (unpaired) or ordinary one-way ANOVA with Tukey's
995 multiple comparisons test. Survival of animals is displayed in Kaplan-Meier survival curves. A *P* value < 0.05
996 was considered as statistically significant, exact *P* values are displayed in the figures. Mice were randomly
997 allocated to the control or treatment groups by the investigator. Mice numbers are indicated as "n" in the figure
998 legends, as well as the number of independent experiments.

999

1000 **Data Availability**

1001 The scRNA-seq raw reads and processed data were submitted to the NCBI GEO database accession number
1002 GSE211575. All code used for data visualization of the scRNA-seq data can be found at
1003 https://github.com/SchlitzerLab/Trained_immunity_2022.

1004

1005 **Code Availability**

1006 All code used for data visualization of the scRNA-seq data can be found at
1007 https://github.com/SchlitzerLab/Trained_immunity_2022.

1008 **Methods-only references**

1009

- 1010 1. Dekkers, J.F., Alieva, M., Wellens, L.M., Ariese, H.C.R., Jamieson, P.R., Vonk, A.M., Amatngalim,
1011 G.D., Hu, H., Oost, K.C., Snippert, H.J.G., et al. (2019). High-resolution 3D imaging of fixed and cleared
1012 organoids. *Nat Protoc* *14*, 1756-1771. 10.1038/s41596-019-0160-8.
- 1013 2. Du, Z., Lin, J.R., Rashid, R., Maliga, Z., Wang, S., Aster, J.C., Izar, B., Sorger, P.K., and Santagata, S.
1014 (2019). Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. *Nat*
1015 *Protoc* *14*, 2900-2930. 10.1038/s41596-019-0206-y.
- 1016 3. Zehender, A., Huang, J., Gyorfı, A.H., Matei, A.E., Trinh-Minh, T., Xu, X., Li, Y.N., Chen, C.W., Lin,
1017 J., Dees, C., et al. (2018). The tyrosine phosphatase SHP2 controls TGFbeta-induced STAT3 signaling
1018 to regulate fibroblast activation and fibrosis. *Nat Commun* *9*, 3259. 10.1038/s41467-018-05768-3.
- 1019 4. Zehender, A., Li, Y.N., Lin, N.Y., Stefanica, A., Nuchel, J., Chen, C.W., Hsu, H.H., Zhu, H., Ding, X.,
1020 Huang, J., et al. (2021). TGFbeta promotes fibrosis by MYST1-dependent epigenetic regulation of
1021 autophagy. *Nat Commun* *12*, 4404. 10.1038/s41467-021-24601-y.
- 1022 5. Bankhead, P., Loughrey, M.B., Fernandez, J.A., Dombrowski, Y., McArt, D.G., Dunne, P.D., McQuaid,
1023 S., Gray, R.T., Murray, L.J., Coleman, H.G., et al. (2017). QuPath: Open source software for digital
1024 pathology image analysis. *Sci Rep* *7*, 16878. 10.1038/s41598-017-17204-5.
- 1025 6. Hubner, R.H., Gitter, W., El Mokhtari, N.E., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., and
1026 Bewig, B. (2008). Standardized quantification of pulmonary fibrosis in histological samples.
1027 *Biotechniques* *44*, 507-511, 514-507. 10.2144/000112729.
- 1028 7. Ashcroft, T., Simpson, J.M., and Timbrell, V. (1988). Simple method of estimating severity of
1029 pulmonary fibrosis on a numerical scale. *J Clin Pathol* *41*, 467-470. 10.1136/jcp.41.4.467.
- 1030 8. Bolte, S., and Cordelieres, F.P. (2006). A guided tour into subcellular colocalization analysis in light
1031 microscopy. *J Microsc* *224*, 213-232. 10.1111/j.1365-2818.2006.01706.x.
- 1032 9. Gierahn, T.M., Wadsworth, M.H., Hughes, T.K., Bryson, B.D., Butler, A., Satija, R., Fortune, S., Love,
1033 J.C., and Shalek, A.K. (2017). Seq-Well: portable, low-cost RNA sequencing of single cells at high
1034 throughput. *Nature Methods* *14*, 395-398. 10.1038/nmeth.4179.
- 1035 10. Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A.R.,
1036 Kamitaki, N., Martersteck, E.M., et al. (2015). Highly Parallel Genome-wide Expression Profiling of
1037 Individual Cells Using Nanoliter Droplets. *Cell* *161*, 1202-1214. 10.1016/j.cell.2015.05.002.
- 1038 11. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk, A.J.,
1039 Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. *Cell* *184*, 3573-
1040 3587 e3529. 10.1016/j.cell.2021.04.048.

1041

1042

1043 **Supplemental Figure Legends** **Supplemental Figure 1 to Figure 1**

1044 (A-F) ScRNA sequencing of the BALF seven days after intranasal stimulation with PBS or β -glucan in wt mice.
1045 (A) Violin plot of feature gene counts per cluster. (B) Violin plot of UMI counts per cluster. (C) Violin plot of
1046 mitochondrial gene percentage per cluster. (D, E) Violin plot of *SiglecF* (D) and *Itgax* (E) RNA expression levels.
1047 (F) Percentage of contribution of condition, PBS or β -glucan, to the five clusters. (G) AM of PBS or β -glucan
1048 treated WT mice were selected by adherence from the BALF 7 days after exposure and subsequently stained with
1049 a 17-plex CODEX antibody panel. Overlay image shows the markers used to identify AM populations. Filled
1050 arrows indicate ApoE⁺CD11b⁺ AMs, whereas open arrows CD11b⁻ AMs. Scale bar represents 10 μ m (n= 2 mice
1051 pooled, two independent experiments). (H) Flow cytometry gating strategy pre-gated on Lin⁻ (Ly6g, B220, CD19,
1052 CD3 ϵ , Nk1.1, Ter-119) and CD45⁺ cells to define ApoE⁺CD11b⁺ AM in the BALF after intranasal PBS or β -
1053 glucan stimulation. (I) Flow cytometric quantification of ApoE⁺CD11b⁺ AM numbers as frequency among AM
1054 in the BALF in a time course from 1 to 21 days post β -glucan stimulation of wt mice (n= 9-10 mice, two
1055 independent experiments). (J, K) Flow cytometric quantification of absolute numbers (J) or frequency (K) of AM
1056 (CD45⁺SiglecF⁺CD64⁺CD11c⁺) among CD45⁺Lin⁻ cells in the BALF in a time course from 1 to 21 days post β -
1057 glucan stimulation of wt mice (n= 9-10 mice, two independent experiments). (L, M) Flow cytometric
1058 quantification of frequency of neutrophils (L) and eosinophils (M) among CD45⁺Lin⁻ cells in the BALF in a time
1059 course from 1 to 21 days post β -glucan stimulation of wt mice (n= 9-10 mice, two independent experiments). (N)
1060 Mean fluorescence Intensity (MFI) of SiglecF on indicated cell subsets in lung seven days post stimulation with
1061 β -glucan (n=4 mice, two independent experiments). (O) UMAP representation of intranasally stimulated lungs
1062 with PBS or β -glucan seven days after stimulation (pooled n=3 mice per condition). Data are depicted as mean \pm
1063 SD, (I-N) ordinary one-way ANOVA with Tukey's multiple comparisons.

1064

1065 **Supplemental Figure 2 to Figure 2**

1066 (A) Quantification of frequency of Ly6c⁺ monocytes among CD45⁺Lin⁻ cells in the BALF in a time course from
1067 1 to 21 days post β -glucan stimulation of WT mice by flow cytometry (n= 9-10 mice, two independent
1068 experiments). (B, C) Percentage of Ly6c⁺ monocytes among CD45⁺Lin⁻ cells in the blood (B) or in the BM (C)
1069 of WT mice seven days after PBS or β -glucan by flow cytometry (n = 6 mice, two individual experiments). (D-
1070 G) Frequency among CD45⁺Lin⁻ cells and absolute numbers of cMOP (D, E) and GMP (F, G) in the BM of WT
1071 mice seven days after PBS or β -glucan by flow cytometry (n = 6 mice, two individual experiments). (H)
1072 Quantification of ApoE⁺CD11b⁺ AM frequency among CD45⁺Lin⁻ cells in the BALF seven days after β -glucan

1073 exposure in WT or CCR2^{-/-} mice (n=7-8 mice, two individual experiments) by flow cytometry. Data are depicted
1074 as mean ± SD, (A, H) ordinary one-way ANOVA with Tukey's multiple comparisons, (B-G) unpaired two-tailed
1075 student's *t*-test.

1076

1077 **Supplemental Figure 3 to Figure 3**

1078 (A) BALF cells were harvested from WT mice seven days after intranasal exposure with PBS or β-glucan and
1079 subsequently restimulated *in vitro* with 10 ng/ml LPS. Representative flow cytometry dot plots of IL-6⁺
1080 ApoE⁺CD11b⁺ AM after restimulation with LPS for 6-8 h followed by intracellular staining gated on
1081 ApoE⁺CD11b⁺ AM (n=6 mice, two independent experiments). (B) Experimental setup of macrophage transfer.
1082 PBS or β-glucan experienced CD45.2⁺ WT macrophages were harvested five days after stimulation and
1083 intratracheally transferred into CD45.1⁺ mice. Readout per flow cytometry or *in vitro* restimulation 48 h after
1084 transfer. (C) Representative flow cytometry plot of the BALF of CD45.1⁺ recipient mice 48 h post transfer of β-
1085 glucan experienced CD45.2⁺ donor macrophages.

1086

1087 **Supplemental Figure 4 to Figure 4**

1088 (A, B) Measurement of glycolytic reserve (A) and glycolytic capacity (B) in BALF cells seven days after PBS or
1089 β-glucan stimulation by extracellular flux analysis (n=6 mice, one independent experiment). (C, D) AM cells from
1090 day seven PBS or β-glucan experienced WT mice were selected by adherence and subsequently treated with 2.5
1091 μm pHrodo *S.aureus* bioparticles (n=3 mice pooled per condition, technical replicates: 6 control wells, 12-19
1092 treated wells per group, one out of two independent experiments shown). (C) Total integrated intensity (OCU x
1093 μm²/image) of the phagocytosis signal in AM over the time course of 7 h (here shown as mean ±SD of all technical
1094 replicates). (D) Quantification of the total integrated intensity in phagocytosis⁺ AM 2 h after adding the pHrodo
1095 *S.aureus* bioparticles. (E) Experimental setup of an acute secondary bacterial infection. Intranasal PBS or β-glucan
1096 stimulation at day zero was followed by intratracheal inoculation with *Legionella pneumophila* at day seven and
1097 sacrifice two days after infection. (F) Experimental setup of a chronic secondary fibrosis challenge. Intranasal
1098 PBS or β-glucan stimulation at day 0 was followed by intratracheal application of *Streptomyces verticillus*
1099 bleomycin at day seven and sacrifice three or 14 days after fibrosis induction. (G-I) Health assessment of mice
1100 after pretreatment with PBS or β-glucan (day 0) prior to fibrosis induction (day 7). (G) Kaplan-Meier plot of
1101 survival (n=35 mice, two independent experiments). (H) Disease burden (general health appearance, spontaneous
1102 behavior, body weight) (n=14 mice, one representative experiment from two independent experiments shown).

1103 (I) Body weight as % change based on the initial weight at day 0 (n=14 mice, one representative experiment from
1104 two independent experiments shown). (J-L) Quantification of IL-4 (J), IL-33 (K) and TSLP (L) protein levels 3
1105 or 14 days after bleomycin treatment (n=6-7 mice, one independent experiment). (M, N) Quantification of the
1106 fibrotic area as percent of the total lung tissue area (M) and the fold change of Ashcroft score (N) by histology 14
1107 days after bleomycin treatment (n=8-11 mice, two independent experiments). (O) Representative confocal images
1108 of lung BALOs co-cultured with PBS- or β -glucan-experienced AM. As a control to TGF- β , AM-BALO co-
1109 cultures were treated with medium only. After fixation, co-cultures were stained for α -SMA (n=6-8 organoids per
1110 condition from two replicate wells, one out of two independent experiments shown). Scale bars represent 50 μ m.
1111 Data are depicted as mean \pm SD, (A-B, L-N) unpaired two-tailed student's *t*-test, (D) ordinary one-way ANOVA
1112 with Tukey's multiple comparisons, (G) Mantel-Cox test, (H, I) ordinary two-way ANOVA with Šídák's multiple
1113 comparisons.

1114

1115 **Supplemental Figure 5 to Figure 5**

1116 (A, B) Frequency of ApoE⁺CD11b⁺ AM among CD45⁺Lin⁻ cells in the BALF (A) seven days after PBS or β -
1117 glucan exposure in Dectin1^{-/-} BM chimeras and the respective blood chimerism for Ly6c⁺ monocytes (B) assessed
1118 by flow cytometry (n=4-10 mice, two independent experiments). (C, D) Frequency of ApoE⁺CD11b⁺ AM among
1119 CD45⁺Lin⁻ cells in the BALF (C) seven days after PBS or β -glucan exposure in CARD9^{-/-} BM chimeras and the
1120 respective blood chimerism for Ly6c⁺ monocytes (D) assessed by flow cytometry (n=8-9 mice, two independent
1121 experiments). Data are depicted as mean \pm SD, (A, C) ordinary one-way ANOVA with Tukey's multiple
1122 comparisons.

1123

1124 **Supplemental Figure 6 to Figure 6**

1125 (A, B) Frequency of ApoE⁺CD11b⁺ AM (A) and Ly6c⁺ monocytes (B) among CD45⁺Lin⁻ cells seven days after
1126 intranasal β -glucan exposure of control or ApoE^{flox}LysM^{Cre} mice by flow cytometry (n=8-10 mice, three
1127 independent experiments). (C-F) Absolute numbers of Ly6c⁺ monocytes in the blood (C) or BM (D), cMOP (E)
1128 and GMP (F) in the BM of control or ApoE^{flox}LysM^{Cre} mice seven days after intranasal β -glucan exposure
1129 quantified by flow cytometry (n=6-8 mice, two independent experiments). (G, H) Lethally irradiated
1130 CD45.1⁺/CD45.2⁺ male mice were reconstituted with 1.5x10⁶ CD45.1⁺ mixed with CD45.2⁺ BM cells (WT/WT)
1131 or with CD45.1⁺ mixed with ApoE^{flox}LysM^{Cre} CD45.2⁺ BM cells (WT/ ApoE^{flox}LysM^{Cre}) for 12 weeks and
1132 subsequently intranasally stimulated with PBS or β -glucan (n=8-9 mice, two independent experiments). Flow

1133 cytometric quantification of ApoE⁺CD11b⁺ AM frequency (G) among CD45⁺Lin⁻ cells and chimerism of Ly6c⁺
1134 monocytes in blood, BALF and BM (H). Bars in (H) are further subdivided into CD45.1⁺ or CD45.2⁺ to display
1135 contribution of transferred mixed BM donors. Data are depicted as mean ± SD, (A-G) ordinary one-way ANOVA
1136 with Tukey's multiple comparisons.

1137

1138 **Supplemental Figure 7 to Figure 7**

1139 (A) Frequency of ApoE⁺CD11b⁺ AM (A) and Ly6c⁺ monocytes (B) among CD45⁺Lin⁻ cells three days after
1140 intranasal β-glucan exposure in control or ApoE^{fllox}LysM^{Cre} mice (n=7-8, two independent experiments) by flow
1141 cytometry. (C) Quantification of M-CSF protein levels in the BALF in a time course from one to 21 days post β-
1142 glucan stimulation of WT mice (n=5 mice, one independent experiment). (D, E) Lungs from WT mice were
1143 harvested 24 h after β-glucan stimulation, fixed, and frozen in OCT. 5 μm sections were prepared and stained
1144 with antibodies to identify AMs and visualize M-CSF production. Representative images are shown in (D).
1145 Arrows indicate ApoE⁺CD11b⁺ AMs. Seven regions of the same size from samples in (D) were acquired and
1146 analyzed as explained in Materials and Methods. Plot in (E) shows the M-CSF mean signal intensities of CD11b⁻
1147 and ApoE⁺CD11b⁺ AMs. Each dot represents an individual cell. (F) Experimental setup of *in vivo* CSF-1R
1148 blockade. WT mice were intranasally stimulated with β-glucan mixed with an anti-CSF-1R antibody or the
1149 respective isotype control and repeatedly treated 12 h and 3 days after initial stimulation. (G- I) Frequency of
1150 ApoE⁺CD11b⁺ AM (G) among CD45⁺Lin⁻ cells and absolute numbers of AM (H) and Ly6c⁺ high monocytes (I)
1151 in the BALF of WT mice seven days after intranasal β-glucan treatment together with 500 μg of CSF-1R antibody
1152 or the respective isotype control (n=8-9 mice, two independent experiments). Data are depicted as mean ± SD,
1153 (A-C) ordinary one-way ANOVA with Tukey's multiple comparisons, (E) Two-tailed Mann-Whitney test, (G-I)
1154 unpaired two-tailed student's *t*-test.